View Profile
Institution: CIB
Research Groups: Translational Medicinal and Biological Chemistry
Position: Research Professor
Contact email: ana.martinez@csic.es
BCB Committee: No committees assigned.
BCB Community: No communities assigned.
BCB Tools: No tools assigned.
BCB Services: No services assigned.
Research topics: Applications of Computational Biology, Drug Discovery and design, Structural bioinformatics, Molecular Interactions/Docking
Publications
Silva-Llanes, I., Madruga, E., Martínez, A., & Lastres-Becker, I. (2025). RIPK1 expression and inhibition in tauopathies: implications for neuroinflammation and neuroprotection. Frontiers in Neuroscience, 18. https://doi.org/10.3389/fnins.2024.1530809
Zeni, M., Santi, M. D., Arredondo, F., Reyes, L., Bentura, M., Carvalho, D., Peralta, M., Ortega, M. G., Abin-Carriquiry, J. A., Martínez-Gonzalez, L., Gambini, J. P., Duarte, P., Martinez, A., Rey, A., & Giglio, J. (2025). 11C-Labeling of a Flavanone Extracted from a South American Native Species for Evaluation of Its Interaction with GSK-3β. Molecules, 30(4), 874. https://doi.org/10.3390/molecules30040874
Aledavood, E., Gil, C., Comabella, M., & Martinez, A. (2025). Discovery of Sphingosine-1-Phosphate Receptor Modulators as Potential CHI3L1 Inhibitors by Ligand-Based Virtual Screening and Molecular Dynamics Simulations. ACS Omega, 10(19), 19992–20000. https://doi.org/10.1021/acsomega.5c01968
Madruga, E., Sanchez-Santos, C., Valenzuela-Martínez, I., Ramírez, D., Gil, C., & Martínez, A. (2025). Discovery of a brain penetrant SGK1 inhibitor using a ligand- and structure-based virtual screening methodology. Journal of Enzyme Inhibition and Medicinal Chemistry, 40(1). https://doi.org/10.1080/14756366.2025.2546591
Zeni, M., Santi, Ma. D., Arredondo, F., Reyes, L., Bentura, M., Carvalho, D., Peralta, M., Ortega, M. G., Abin-Carriquiry, J. A., Martínez-Gonzalez, L., Gambini, J. P., Duarte, P., Martinez, A., Rey, A., & Giglio, J. (2024). 11C-Labeling of a Flavone Extracted from a South American Native Species for Evaluation of Its Interaction with Gsk-3β. https://doi.org/10.20944/preprints202411.0227.v1
Benítez‐Fernández, R., Josa‐Prado, F., Sánchez, E., Lao, Y., García‐Rubia, A., Cumella, J., Martínez, A., Palomo, V., & de Castro, F. (2024). Efficacy of a benzothiazole‐based LRRK2 inhibitor in oligodendrocyte precursor cells and in a murine model of multiple sclerosis. CNS Neuroscience & Therapeutics, 30(1). Portico. https://doi.org/10.1111/cns.14552
Morales-Tenorio, M., Lasala, F., Garcia-Rubia, A., Aledavood, E., Heung, M., Olal, C., Escudero-Pérez, B., Alonso, C., Martínez, A., Muñoz-Fontela, C., Delgado, R., & Gil, C. (2024). Discovery of Thiophene Derivatives as Potent, Orally Bioavailable, and Blood–Brain Barrier-Permeable Ebola Virus Entry Inhibitors. Journal of Medicinal Chemistry, 67(18), 16381–16402. https://doi.org/10.1021/acs.jmedchem.4c01267
Pérez de la Lastra Aranda, C., Tosat-Bitrián, C., Porras, G., Dafinca, R., Muñoz-Torrero, D., Talbot, K., Martín-Requero, Á., Martínez, A., & Palomo, V. (2024). Proteome Aggregation in Cells Derived from Amyotrophic Lateral Sclerosis Patients for Personalized Drug Evaluation. ACS Chemical Neuroscience, 15(21), 3945–3953. https://doi.org/10.1021/acschemneuro.4c00328
Rojas-Prats, E., Martinez-Gonzalez, L., Gil, C., Ramírez, D., & Martinez, A. (2024). Druggable cavities and allosteric modulators of the cell division cycle 7 (CDC7) kinase. Journal of Enzyme Inhibition and Medicinal Chemistry, 39(1). https://doi.org/10.1080/14756366.2024.2301767
Tosat-Bitrián, C., Martínez-González, L., Cuevas, E. P., Martínez, A., & Palomo, V. (2024). TDP-43 Modulation for the Treatment of Neurodegenerative Diseases: Rationale and Assay Methodologies. Methods in Neurodegenerative Disease Drug Discovery, 87–104. https://doi.org/10.1007/978-1-0716-4232-0_4
Martinez-Gonzalez, L., & Martinez, A. (2023). Emerging clinical investigational drugs for the treatment of amyotrophic lateral sclerosis. Expert Opinion on Investigational Drugs, 32(2), 141–160. https://doi.org/10.1080/13543784.2023.2178416
Porras, G., Ruiz, S., Maestro, I., Borrego-Hernández, D., Redondo, A. G., Martínez, A., & Martín-Requero, Á. (2023). Functional Characterization of a Familial ALS-Associated Missense TBK1 (p-Arg573Gly) Mutation in Patient-Derived Lymphoblasts. International Journal of Molecular Sciences, 24(3), 2847. https://doi.org/10.3390/ijms24032847
Rodríguez-Periñán, G., de la Encarnación, A., Moreno, F., López de Munain, A., Martínez, A., Martín-Requero, Á., Alquézar, C., & Bartolomé, F. (2023). Progranulin Deficiency Induces Mitochondrial Dysfunction in Frontotemporal Lobar Degeneration with TDP-43 Inclusions. Antioxidants, 12(3), 581. https://doi.org/10.3390/antiox12030581
Zheng, Y., Schroeder, S., Kanev, G. K., Botros, S. S., William, S., Sabra, A.-N. A., Maes, L., Caljon, G., Gil, C., Martinez, A., Salado, I. G., Augustyns, K., Edink, E., Sijm, M., de Heuvel, E., de Esch, I. J. P., van der Meer, T., Siderius, M., Sterk, G. J., … Leurs, R. (2023). To Target or Not to Target Schistosoma mansoni Cyclic Nucleotide Phosphodiesterase 4A? International Journal of Molecular Sciences, 24(7), 6817. https://doi.org/10.3390/ijms24076817
Garcia-Rubia, A., Lasala, F., Ginex, T., Morales-Tenorio, M., Olal, C., Heung, M., Oquist, P., Galindo, I., Cuesta-Geijo, M. Á., Casasnovas, J. M., Campillo, N. E., Canales, Á., Alonso, C., Martínez, A., Muñoz-Fontela, C., Delgado, R., & Gil, C. (2023). N′-Phenylacetohydrazide Derivatives as Potent Ebola Virus Entry Inhibitors with an Improved Pharmacokinetic Profile. Journal of Medicinal Chemistry, 66(8), 5465–5483. https://doi.org/10.1021/acs.jmedchem.2c01785
Moreno, R., Recio, J., Barber, S., Gil, C., & Martinez, A. (2023). The emerging role of mixed lineage kinase 3 (MLK3) and its potential as a target for neurodegenerative diseases therapies. European Journal of Medicinal Chemistry, 257, 115511. https://doi.org/10.1016/j.ejmech.2023.115511
Maestro, I., Madruga, E., Boya, P., & Martínez, A. (2023). Identification of a new structural family of SGK1 inhibitors as potential neuroprotective agents. Journal of Enzyme Inhibition and Medicinal Chemistry, 38(1). https://doi.org/10.1080/14756366.2022.2153841
Nozal, V., Martínez-González, L., Gomez-Almeria, M., Gonzalo-Consuegra, C., Santana, P., Chaikuad, A., Pérez-Cuevas, E., Knapp, S., Lietha, D., Ramírez, D., Petralla, S., Monti, B., Gil, C., Martín-Requero, A., Palomo, V., de Lago, E., & Martinez, A. (2022). TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy. Journal of Medicinal Chemistry, 65(2), 1585–1607. https://doi.org/10.1021/acs.jmedchem.1c01942
Cuevas, E. P., Rodríguez-Fernández, A., Palomo, V., Martínez, A., & Martín-Requero, Á. (2022). TDP-43 Pathology and Prionic Behavior in Human Cellular Models of Alzheimer’s Disease Patients. Biomedicines, 10(2), 385. https://doi.org/10.3390/biomedicines10020385
Martín-Cámara, O., Arribas, M., Wells, G., Morales-Tenorio, M., Martín-Requero, Á., Porras, G., Martínez, A., Giorgi, G., López-Alvarado, P., Lastres-Becker, I., & Menéndez, J. C. (2022). Multitarget Hybrid Fasudil Derivatives as a New Approach to the Potential Treatment of Amyotrophic Lateral Sclerosis. Journal of Medicinal Chemistry, 65(3), 1867–1882. https://doi.org/10.1021/acs.jmedchem.1c01255
Méndez-Líter, J. A., Pozo-Rodríguez, A., Madruga, E., Rubert, M., Santana, A. G., de Eugenio, L. I., Sánchez, C., Martínez, A., Prieto, A., & Martínez, M. J. (2022). Glycosylation of Epigallocatechin Gallate by Engineered Glycoside Hydrolases from Talaromyces amestolkiae: Potential Antiproliferative and Neuroprotective Effect of These Molecules. Antioxidants, 11(7), 1325. https://doi.org/10.3390/antiox11071325
Alegría-Arcos, M., Barbosa, T., Sepúlveda, F., Combariza, G., González, J., Gil, C., Martínez, A., & Ramírez, D. (2022). Network pharmacology reveals multitarget mechanism of action of drugs to be repurposed for COVID-19. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.952192
Lastres-Becker, I., de Lago, E., Martínez, A., & Fernández-Ruiz, J. (2022). New Statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Biomolecules, 12(9), 1200. https://doi.org/10.3390/biom12091200
Reggiori, F., Boya, P., da Costa, D., Elazar, Z., Eskelinen, E.-L., Farrés, J., Guettler, S., Kraft, C., Jungbluth, H., Martinez, A., Morel, E., Pless, O., Proikas-Cezanne, T., & Simonsen, A. (2022). The mechanism of macroautophagy: The movie. Autophagy Reports, 1(1), 414–417. https://doi.org/10.1080/27694127.2022.2096115
Maestro, I., de la Ballina, L. R., Porras, G., Corrochano, S., De Lago, E., Simonsen, A., Boya, P., & Martinez, A. (2022). Discovery of Mitophagy Inhibitors with Therapeutic Potential in Different Familial Amyotrophic Lateral Sclerosis Mutations. International Journal of Molecular Sciences, 23(20), 12676. https://doi.org/10.3390/ijms232012676
Cogram, P., Fernández-Beltrán, L. C., Casarejos, M. J., Sánchez-Yepes, S., Rodríguez-Martín, E., García-Rubia, A., Sánchez-Barrena, M. J., Gil, C., Martínez, A., & Mansilla, A. (2022). The inhibition of NCS-1 binding to Ric8a rescues fragile X syndrome mice model phenotypes. Frontiers in Neuroscience, 16. https://doi.org/10.3389/fnins.2022.1007531
Benítez-Fernández, R., Gil, C., Guaza, C., Mestre, L., & Martínez, A. (2022). The Dual PDE7-GSK3β Inhibitor, VP3.15, as Neuroprotective Disease-Modifying Treatment in a Model of Primary Progressive Multiple Sclerosis. International Journal of Molecular Sciences, 23(22), 14378. https://doi.org/10.3390/ijms232214378
Vila Méndez, M. L., Antón Sanz, C., Cárdenas García, A. del R., Bravo Malo, A., Torres Martínez, F. J., Martín Moros, J. M., Real Torrijos, M., Vendrell Covisa, J. F. J., Guzmán Sierra, O., Molina Barcena, V., Viejo Pinero, N., Fernández Díaz, C., Arroyo Burguillo, P., Blanco Gallego, A. M., Guirao Sánchez, C., Montilla Bernabé, A., Villanueva Morán, M. del P., Juárez Antón, S., Fernández Rodríguez, Á., … Soler López, B. (2022). Efficacy of Bromhexine versus Standard of Care in Reducing Viral Load in Patients with Mild-to-Moderate COVID-19 Disease Attended in Primary Care: A Randomized Open-Label Trial. Journal of Clinical Medicine, 12(1), 142. https://doi.org/10.3390/jcm12010142
Rojas-Prats, E., Martinez-Gonzalez, L., Gonzalo-Consuegra, C., Liachko, N. F., Perez, C., Ramírez, D., Kraemer, B. C., Martin-Requero, Á., Perez, D. I., Gil, C., de Lago, E., & Martinez, A. (2021). Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis. European Journal of Medicinal Chemistry, 210, 112968. https://doi.org/10.1016/j.ejmech.2020.112968
Madruga, E., Maestro, I., & Martínez, A. (2021). Mitophagy Modulation, a New Player in the Race against ALS. International Journal of Molecular Sciences, 22(2), 740. https://doi.org/10.3390/ijms22020740
Rojas-Prats, E., Tosat-Bitrián, C., Martínez-González, L., Nozal, V., Pérez, D. I., & Martínez, A. (2021). Increasing Brain Permeability of PHA-767491, a Cell Division Cycle 7 Kinase Inhibitor, with Biodegradable Polymeric Nanoparticles. Pharmaceutics, 13(2), 180. https://doi.org/10.3390/pharmaceutics13020180
Lasala, F., García-Rubia, A., Requena, C., Galindo, I., Cuesta-Geijo, M. A., García-Dorival, I., Bueno, P., Labiod, N., Luczkowiak, J., Martinez, A., Campillo, N. E., Alonso, C., Delgado, R., & Gil, C. (2021). Identification of potential inhibitors of protein-protein interaction useful to fight against Ebola and other highly pathogenic viruses. Antiviral Research, 186, 105011. https://doi.org/10.1016/j.antiviral.2021.105011
Davies, M. P., Benitez, R., Perez, C., Jakupovic, S., Welsby, P., Rzepecka, K., Alder, J., Davidson, C., Martinez, A., & Hayes, J. M. (2021). Structure-Based Design of Potent Selective Nanomolar Type-II Inhibitors of Glycogen Synthase Kinase-3β. Journal of Medicinal Chemistry, 64(3), 1497–1509. https://doi.org/10.1021/acs.jmedchem.0c01568
Benítez-Fernández, R., Melero-Jerez, C., Gil, C., de la Rosa, E. J., Martínez, A., & de Castro, F. (2021). Dynamics of Central Remyelination and Treatment Evolution in a Model of Multiple Sclerosis with Optic Coherence Tomography. International Journal of Molecular Sciences, 22(5), 2440. https://doi.org/10.3390/ijms22052440
Lastres-Becker, I., Porras, G., Arribas-Blázquez, M., Maestro, I., Borrego-Hernández, D., Boya, P., Cerdán, S., García-Redondo, A., Martínez, A., & Martin-Requero, Á. (2021). Molecular Alterations in Sporadic and SOD1-ALS Immortalized Lymphocytes: Towards a Personalized Therapy. International Journal of Molecular Sciences, 22(6), 3007. https://doi.org/10.3390/ijms22063007
Nozal, V., Rojas-Prats, E., Maestro, I., Gil, C., Perez, D., & Martinez, A. (2021). Improved Controlled Release and Brain Penetration of the Small Molecule S14 Using PLGA Nanoparticles. International Journal of Molecular Sciences, 22(6), 3206. https://doi.org/10.3390/ijms22063206
Grieco, I., Bissaro, M., Tiz, D. B., Perez, D. I., Perez, C., Martinez, A., Redenti, S., Mariotto, E., Bortolozzi, R., Viola, G., Cozza, G., Spalluto, G., Moro, S., & Federico, S. (2021). Developing novel classes of protein kinase CK1δ inhibitors by fusing [1,2,4]triazole with different bicyclic heteroaromatic systems. European Journal of Medicinal Chemistry, 216, 113331. https://doi.org/10.1016/j.ejmech.2021.113331
Ginex, T., Garaigorta, U., Ramírez, D., Castro, V., Nozal, V., Maestro, I., García-Cárceles, J., Campillo, N. E., Martinez, A., Gastaminza, P., & Gil, C. (2021). Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods. Pharmaceuticals, 14(4), 332. https://doi.org/10.3390/ph14040332
Rico, A., Guembelzu, G., Palomo, V., Martínez, A., Aiastui, A., Casas-Fraile, L., Valls, A., López de Munain, A., & Sáenz, A. (2021). Allosteric Modulation of GSK-3β as a New Therapeutic Approach in Limb Girdle Muscular Dystrophy R1 Calpain 3-Related. International Journal of Molecular Sciences, 22(14), 7367. https://doi.org/10.3390/ijms22147367
Gil, C., & Martinez, A. (2021). Is drug repurposing really the future of drug discovery or is new innovation truly the way forward? Expert Opinion on Drug Discovery, 16(8), 829–831. https://doi.org/10.1080/17460441.2021.1912733
Martínez-González, L., Gonzalo-Consuegra, C., Gómez-Almería, M., Porras, G., de Lago, E., Martín-Requero, Á., & Martínez, A. (2021). Tideglusib, a Non-ATP Competitive Inhibitor of GSK-3β as a Drug Candidate for the Treatment of Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences, 22(16), 8975. https://doi.org/10.3390/ijms22168975
Nozal, V., García‐Rubia, A., Cuevas, E. P., Pérez, C., Tosat‐Bitrián, C., Bartolomé, F., Carro, E., Ramírez, D., Palomo, V., & Martínez, A. (2021). From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer’s Disease using Protein‐Templated Synthesis. Angewandte Chemie, 133(35), 19493–19503. Portico. https://doi.org/10.1002/ange.202106295
García-Dorival, I., Cuesta-Geijo, M. Á., Barrado-Gil, L., Galindo, I., Garaigorta, U., Urquiza, J., Puerto, A. del, Campillo, N. E., Martínez, A., Gastaminza, P., Gil, C., & Alonso, C. (2021). Identification of Niemann-Pick C1 protein as a potential novel SARS-CoV-2 intracellular target. Antiviral Research, 194, 105167. https://doi.org/10.1016/j.antiviral.2021.105167
Berenguer, E., Carneros, E., Pérez-Pérez, Y., Gil, C., Martínez, A., & Testillano, P. S. (2021). Small molecule inhibitors of mammalian GSK-3β promote in vitro plant cell reprogramming and somatic embryogenesis in crop and forest species. Journal of Experimental Botany, 72(22), 7808–7825. https://doi.org/10.1093/jxb/erab365
Maestro, I., de la Ballina, L. R., Simonsen, A., Boya, P., & Martinez, A. (2021). Phenotypic Assay Leads to Discovery of Mitophagy Inducers with Therapeutic Potential for Parkinson’s Disease. ACS Chemical Neuroscience, 12(24), 4512–4523. https://doi.org/10.1021/acschemneuro.1c00529
Alaohali, A., Salzlechner, C., Zaugg, L. K., Suzano, F., Martinez, A., Gentleman, E., & Sharpe, P. T. (2021). GSK3 Inhibitor-Induced Dentinogenesis Using a Hydrogel. Journal of Dental Research, 101(1), 46–53. https://doi.org/10.1177/00220345211020652
García-Cárceles, J., Caballero, E., Gil, C., & Martínez, A. (2021). Kinase Inhibitors as Underexplored Antiviral Agents. Journal of Medicinal Chemistry, 65(2), 935–954. https://doi.org/10.1021/acs.jmedchem.1c00302
Giglio, J., Fernandez, S., Martinez, A., Zeni, M., Reyes, L., Rey, A., & Cerecetto, H. (2021). Glycogen Synthase Kinase-3 Maleimide Inhibitors As Potential PET-Tracers for Imaging Alzheimer’s Disease: 11C-Synthesis and In Vivo Proof of Concept. Journal of Medicinal Chemistry, 65(2), 1342–1351. https://doi.org/10.1021/acs.jmedchem.1c00769
Kocak, M., Ezazi Erdi, S., Jorba, G., Maestro, I., Farrés, J., Kirkin, V., Martinez, A., & Pless, O. (2021). Targeting autophagy in disease: established and new strategies. Autophagy, 18(3), 473–495. https://doi.org/10.1080/15548627.2021.1936359
Lassagne, F., Duguépéroux, C., Roca, C., Perez, C., Martinez, A., Baratte, B., Robert, T., Ruchaud, S., Bach, S., Erb, W., Roisnel, T., & Mongin, F. (2020). From simple quinoxalines to potent oxazolo[5,4-f]quinoxaline inhibitors of glycogen-synthase kinase 3 (GSK3). Organic & Biomolecular Chemistry, 18(1), 154–162. https://doi.org/10.1039/c9ob02002k
Sebastian-Perez, V., García-Rubia, A., Seif el-Din, S. H., Sabra, A.-N. A., El-Lakkany, N. M., William, S., Blundell, T. L., Maes, L., Martinez, A., Campillo, N. E., Botros, S. S., & Gil, C. (2020). Deciphering the enzymatic target of a new family of antischistosomal agents bearing a quinazoline scaffold using complementary computational tools. Journal of Enzyme Inhibition and Medicinal Chemistry, 35(1), 511–523. https://doi.org/10.1080/14756366.2020.1712595
Maestro, I., Boya, P., & Martinez, A. (2020). Serum- and glucocorticoid-induced kinase 1, a new therapeutic target for autophagy modulation in chronic diseases. Expert Opinion on Therapeutic Targets, 24(3), 231–243. https://doi.org/10.1080/14728222.2020.1730328
Martínez-González, L., Rodríguez-Cueto, C., Cabezudo, D., Bartolomé, F., Andrés-Benito, P., Ferrer, I., Gil, C., Martín-Requero, Á., Fernández-Ruiz, J., Martínez, A., & de Lago, E. (2020). Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment. Scientific Reports, 10(1). https://doi.org/10.1038/s41598-020-61265-y
Peřinová, R., Maafi, N., Korábečný, J., Kohelová, E., De Simone, A., Al Mamun, A., Hulcová, D., Marková, J., Kučera, T., Jun, D., Šafratová, M., Maříková, J., Andrisano, V., Jenčo, J., Kuneš, J., Martinez, A., Nováková, L., & Cahlíková, L. (2020). Functionalized aromatic esters of the Amaryllidaceae alkaloid haemanthamine and their in vitro and in silico biological activity connected to Alzheimer’s disease. Bioorganic Chemistry, 100, 103928. https://doi.org/10.1016/j.bioorg.2020.103928
Di Martino, R. M. C., Pruccoli, L., Bisi, A., Gobbi, S., Rampa, A., Martinez, A., Pérez, C., Martinez-Gonzalez, L., Paglione, M., Di Schiavi, E., Seghetti, F., Tarozzi, A., & Belluti, F. (2020). Novel Curcumin-Diethyl Fumarate Hybrid as a Dualistic GSK-3β Inhibitor/Nrf2 Inducer for the Treatment of Parkinson’s Disease. ACS Chemical Neuroscience, 11(17), 2728–2740. https://doi.org/10.1021/acschemneuro.0c00363
Gil, C., Ginex, T., Maestro, I., Nozal, V., Barrado-Gil, L., Cuesta-Geijo, M. Á., Urquiza, J., Ramírez, D., Alonso, C., Campillo, N. E., & Martinez, A. (2020). COVID-19: Drug Targets and Potential Treatments. Journal of Medicinal Chemistry, 63(21), 12359–12386. https://doi.org/10.1021/acs.jmedchem.0c00606
Castro-Sánchez, S., Zaldivar-Diez, J., Luengo, E., López, M. G., Gil, C., Martínez, A., & Lastres-Becker, I. (2020). Cognitive enhancement, TAU phosphorylation reduction, and neuronal protection by the treatment of an LRRK2 inhibitor in a tauopathy mouse model. Neurobiology of Aging, 96, 148–154. https://doi.org/10.1016/j.neurobiolaging.2020.09.006
Vaca, G., Martinez‐Gonzalez, L., Fernandez, A., Rojas‐Prats, E., Porras, G., Cuevas, E. P., Gil, C., Martinez, A., & Martin‐Requero, Á. (2020). Therapeutic potential of novel Cell Division Cycle Kinase 7 inhibitors on TDP‐43‐related pathogenesis such as Frontotemporal Lobar Degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). Journal of Neurochemistry, 156(3), 379–390. Portico. https://doi.org/10.1111/jnc.15118
Palomo, V., Nozal, V., Rojas‐Prats, E., Gil, C., & Martinez, A. (2020). Protein kinase inhibitors for amyotrophic lateral sclerosis therapy. British Journal of Pharmacology, 178(6), 1316–1335. Portico. https://doi.org/10.1111/bph.15221
Gürbüz, P., Martinez, A., Pérez, C., Martínez-González, L., Göger, F., & Ayran, İ. (2019). Potential anti-Alzheimer effects of selected Lamiaceae plants through polypharmacology on glycogen synthase kinase-3β, β-secretase, and casein kinase 1δ. Industrial Crops and Products, 138, 111431. https://doi.org/10.1016/j.indcrop.2019.05.080
de Andrade, P., Mantoani, S. P., Gonçalves Nunes, P. S., Magadán, C. R., Pérez, C., Xavier, D. J., Hojo, E. T. S., Campillo, N. E., Martínez, A., & Carvalho, I. (2019). Highly potent and selective aryl-1,2,3-triazolyl benzylpiperidine inhibitors toward butyrylcholinesterase in Alzheimer’s disease. Bioorganic & Medicinal Chemistry, 27(6), 931–943. https://doi.org/10.1016/j.bmc.2018.12.030
Sánchez-Cruz, A., Martínez, A., de la Rosa, E. J., & Hernández-Sánchez, C. (2019). GSK-3 Inhibitors: From the Brain to the Retina and Back Again. Retinal Degenerative Diseases, 437–441. https://doi.org/10.1007/978-3-030-27378-1_72
Sebastián-Pérez, V., Schroeder, S., Munday, J. C., van der Meer, T., Zaldívar-Díez, J., Siderius, M., de Koning, H. P., Brown, D., Martínez, A., Campillo, N. E., Leurs, R., & Gil, C. (2019). Discovery of NovelSchistosoma MansoniPDE4A Inhibitors as Potential Agents against Schistosomiasis. Future Medicinal Chemistry, 11(14), 1703–1720. https://doi.org/10.4155/fmc-2018-0592
Wang, M., Weng, W.-C., Stock, L., Lindquist, D., Martinez, A., Gourdon, G., Timchenko, N., Snape, M., & Timchenko, L. (2019). Correction of Glycogen Synthase Kinase 3β in Myotonic Dystrophy 1 Reduces the Mutant RNA and Improves Postnatal Survival of DMSXL Mice. Molecular and Cellular Biology, 39(21). https://doi.org/10.1128/mcb.00155-19
Martinez, A., & Gil, C. (2019). Protein Kinase Inhibitors for the Treatment of Multiple Sclerosis. Emerging Drugs and Targets for Multiple Sclerosis, 170–196. https://doi.org/10.1039/9781788016070-00170
Redenti, S., Marcovich, I., De Vita, T., Pérez, C., De Zorzi, R., Demitri, N., Perez, D. I., Bottegoni, G., Bisignano, P., Bissaro, M., Moro, S., Martinez, A., Storici, P., Spalluto, G., Cavalli, A., & Federico, S. (2019). A Triazolotriazine‐Based Dual GSK‐3β/CK‐1δ Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic Inhibition. ChemMedChem, 14(3), 310–314. Portico. https://doi.org/10.1002/cmdc.201800778
Venter, J., Perez, C., van Otterlo, W. A. L., Martínez, A., & Blackie, M. A. L. (2019). 1-Aryl-3-(4-methoxybenzyl)ureas as potentially irreversible glycogen synthase kinase 3 inhibitors: Synthesis and biological evaluation. Bioorganic & Medicinal Chemistry Letters, 29(13), 1597–1600. https://doi.org/10.1016/j.bmcl.2019.04.049
Nozal, V., & Martinez, A. (2019). Tau Tubulin Kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseases. European Journal of Medicinal Chemistry, 161, 39–47. https://doi.org/10.1016/j.ejmech.2018.10.030
Sebastián-Pérez, V., Martínez, M. J., Gil, C., Campillo, N. E., Martínez, A., & Ponzoni, I. (2019). QSAR Modelling to Identify LRRK2 Inhibitors for Parkinson’s Disease. Journal of Integrative Bioinformatics, 16(1). https://doi.org/10.1515/jib-2018-0063
Palomo, V., Tosat-Bitrian, C., Nozal, V., Nagaraj, S., Martin-Requero, A., & Martinez, A. (2019). TDP-43: A Key Therapeutic Target beyond Amyotrophic Lateral Sclerosis. ACS Chemical Neuroscience, 10(3), 1183–1196. https://doi.org/10.1021/acschemneuro.9b00026
Canal-Martín, A., Sastre, J., Sánchez-Barrena, M. J., Canales, A., Baldominos, S., Pascual, N., Martínez-González, L., Molero, D., Fernández-Valle, M. E., Sáez, E., Blanco-Gabella, P., Gómez-Rubio, E., Martín-Santamaría, S., Sáiz, A., Mansilla, A., Cañada, F. J., Jiménez-Barbero, J., Martínez, A., & Pérez-Fernández, R. (2019). Insights into real-time chemical processes in a calcium sensor protein-directed dynamic library. Nature Communications, 10(1). https://doi.org/10.1038/s41467-019-10627-w
Morales-Navarro, S., Prent-Peñaloza, L., Rodríguez Núñez, Y. A., Sánchez-Aros, L., Forero-Doria, O., González, W., Campilllo, N. E., Reyes-Parada, M., Martínez, A., & Ramírez, D. (2019). Theoretical and Experimental Approaches Aimed at Drug Design Targeting Neurodegenerative Diseases. Processes, 7(12), 940. https://doi.org/10.3390/pr7120940
Martínez de Iturrate, P., Sebastián-Pérez, V., Nácher-Vázquez, M., Tremper, C. S., Smirlis, D., Martín, J., Martínez, A., Campillo, N. E., Rivas, L., & Gil, C. (2019). Towards discovery of new leishmanicidal scaffolds able to inhibitLeishmaniaGSK-3. Journal of Enzyme Inhibition and Medicinal Chemistry, 35(1), 199–210. https://doi.org/10.1080/14756366.2019.1693704
Zaldivar-Diez, J., Li, L., Garcia, A. M., Zhao, W.-N., Medina-Menendez, C., Haggarty, Stephen. J., Gil, C., Morales, A. V., & Martinez, A. (2019). Benzothiazole-Based LRRK2 Inhibitors as Wnt Enhancers and Promoters of Oligodendrocytic Fate. Journal of Medicinal Chemistry, 63(5), 2638–2655. https://doi.org/10.1021/acs.jmedchem.9b01752
Cheng, Y., Desse, S., Martinez, A., Worthen, R. J., Jope, R. S., & Beurel, E. (2018). TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice. Brain, Behavior, and Immunity, 69, 556–567. https://doi.org/10.1016/j.bbi.2018.02.003
Sebastián-Pérez, V., Hendrickx, S., Munday, J. C., Kalejaiye, T., Martínez, A., Campillo, N. E., de Koning, H., Caljon, G., Maes, L., & Gil, C. (2018). Cyclic Nucleotide-Specific Phosphodiesterases as Potential Drug Targets for Anti-Leishmania Therapy. Antimicrobial Agents and Chemotherapy, 62(10). https://doi.org/10.1128/aac.00603-18
Chierrito, T. P. C., Pedersoli-Mantoani, S., Roca, C., Sebastian-Pérez, V., Martínez-Gonzalez, L., Pérez, D. I., Perez, C., Canales, A., Cañada, F. J., Campillo, N. E., Carvalho, I., & Martinez, A. (2018). Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. European Journal of Medicinal Chemistry, 145, 431–444. https://doi.org/10.1016/j.ejmech.2018.01.007
Bartolome, F., de la Cueva, M., Pascual, C., Antequera, D., Fernandez, T., Gil, C., Martinez, A., & Carro, E. (2018). Amyloid β-induced impairments on mitochondrial dynamics, hippocampal neurogenesis, and memory are restored by phosphodiesterase 7 inhibition. Alzheimer’s Research & Therapy, 10(1). https://doi.org/10.1186/s13195-018-0352-4
Roca, C., Requena, C., Sebastián-Pérez, V., Malhotra, S., Radoux, C., Pérez, C., Martinez, A., Antonio Páez, J., Blundell, T. L., & Campillo, N. E. (2018). Identification of new allosteric sites and modulators of AChE through computational and experimental tools. Journal of Enzyme Inhibition and Medicinal Chemistry, 33(1), 1034–1047. https://doi.org/10.1080/14756366.2018.1476502
Benek, O., Hroch, L., Aitken, L., Gunn-Moore, F., Vinklarova, L., Kuca, K., Perez, D. I., Perez, C., Martinez, A., Fisar, Z., & Musilek, K. (2018). 1-(Benzo[d]thiazol-2-yl)-3-phenylureas as dual inhibitors of casein kinase 1 and ABAD enzymes for treatment of neurodegenerative disorders. Journal of Enzyme Inhibition and Medicinal Chemistry, 33(1), 665–670. https://doi.org/10.1080/14756366.2018.1445736
Sánchez-Cruz, A., Villarejo-Zori, B., Marchena, M., Zaldivar-Díez, J., Palomo, V., Gil, C., Lizasoain, I., de la Villa, P., Martínez, A., de la Rosa, E. J., & Hernández-Sánchez, C. (2018). Modulation of GSK-3 provides cellular and functional neuroprotection in the rd10 mouse model of retinitis pigmentosa. Molecular Neurodegeneration, 13(1). https://doi.org/10.1186/s13024-018-0251-y
Decara, J., Serrano, A., Pavón, F. J., Rivera, P., Arco, R., Gavito, A., Vargas, A., Navarro, J. A., Tovar, R., Lopez-Gambero, A. J., Martínez, A., Suárez, J., Rodríguez de Fonseca, F., & Baixeras, E. (2018). The adiponectin promoter activator NP-1 induces high levels of circulating TNFα and weight loss in obese (fa/fa) Zucker rats. Scientific Reports, 8(1). https://doi.org/10.1038/s41598-018-27871-7
Posa, D., Martínez-González, L., Bartolomé, F., Nagaraj, S., Porras, G., Martínez, A., & Martín-Requero, Á. (2018). Recapitulation of Pathological TDP-43 Features in Immortalized Lymphocytes from Sporadic ALS Patients. Molecular Neurobiology, 56(4), 2424–2432. https://doi.org/10.1007/s12035-018-1249-8
Roca, C., Martinez-González, L., Daniel-Mozo, M., Sastre, J., Infantes, L., Mansilla, A., Chaves-Sanjuan, A., González-Rubio, J. M., Gil, C., Cañada, F. J., Martinez, A., Sanchez-Barrena, M. J., & Campillo, N. E. (2018). Deciphering the Inhibition of the Neuronal Calcium Sensor 1 and the Guanine Exchange Factor Ric8a with a Small Phenothiazine Molecule for the Rational Generation of Therapeutic Synapse Function Regulators. Journal of Medicinal Chemistry, 61(14), 5910–5921. https://doi.org/10.1021/acs.jmedchem.8b00088
Gandini, A., Bartolini, M., Tedesco, D., Martinez-Gonzalez, L., Roca, C., Campillo, N. E., Zaldivar-Diez, J., Perez, C., Zuccheri, G., Miti, A., Feoli, A., Castellano, S., Petralla, S., Monti, B., Rossi, M., Moda, F., Legname, G., Martinez, A., & Bolognesi, M. L. (2018). Tau-Centric Multitarget Approach for Alzheimer’s Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors. Journal of Medicinal Chemistry, 61(17), 7640–7656. https://doi.org/10.1021/acs.jmedchem.8b00610
Alten, B., Yesiltepe, M., Bayraktar, E., Tas, S. T., Gocmen, A. Y., Kursungoz, C., Martinez, A., & Sara, Y. (2018). High‐fructose corn syrup consumption in adolescent rats causes bipolar‐like behavioural phenotype with hyperexcitability in hippocampal CA3‐CA1 synapses. British Journal of Pharmacology, 175(24), 4450–4463. Portico. https://doi.org/10.1111/bph.14500
Sebastián-Pérez, V., Martínez, M. J., Gil, C., Campillo, N. E., Martínez, A., & Ponzoni, I. (2018). QSAR Modelling for Drug Discovery: Predicting the Activity of LRRK2 Inhibitors for Parkinson’s Disease Using Cheminformatics Approaches. Practical Applications of Computational Biology and Bioinformatics, 12th International Conference, 63–70. https://doi.org/10.1007/978-3-319-98702-6_8
Sciú, M. L., Sebastián-Pérez, V., Martinez-Gonzalez, L., Benitez, R., Perez, D. I., Pérez, C., Campillo, N. E., Martinez, A., & Moyano, E. L. (2018). Computer-aided molecular design of pyrazolotriazines targeting glycogen synthase kinase 3. Journal of Enzyme Inhibition and Medicinal Chemistry, 34(1), 87–96. https://doi.org/10.1080/14756366.2018.1530223
Uliassi, E., Peña-Altamira, L. E., Morales, A. V., Massenzio, F., Petralla, S., Rossi, M., Roberti, M., Martinez Gonzalez, L., Martinez, A., Monti, B., & Bolognesi, M. L. (2018). A Focused Library of Psychotropic Analogues with Neuroprotective and Neuroregenerative Potential. ACS Chemical Neuroscience, 10(1), 279–294. https://doi.org/10.1021/acschemneuro.8b00242
Kraft, C., Boya, P., Codogno, P., Elazar, Z., Eskelinen, E.-L., Farrés, J., Kirkin, V., Jungbluth, H., Martinez, A., Pless, O., Primard, C., Proikas-Cezanne, T., Simonsen, A., & Reggiori, F. (2018). Driving next-generation autophagy researchers towards translation (DRIVE), an international PhD training program on autophagy. Autophagy, 15(2), 347–351. https://doi.org/10.1080/15548627.2018.1515532
Pérez-Domper, P., Palomo, V., Gradari, S., Gil, C., de Ceballos, M. L., Martínez, A., & Trejo, J. L. (2017). The GSK-3-inhibitor VP2.51 produces antidepressant effects associated with adult hippocampal neurogenesis. Neuropharmacology, 116, 174–187. https://doi.org/10.1016/j.neuropharm.2016.12.019
Marchena, M., Villarejo-Zori, B., Zaldivar-Diez, J., Palomo, V., Gil, C., Hernández-Sánchez, C., Martínez, A., & de la Rosa, E. J. (2017). Small molecules targeting glycogen synthase kinase 3 as potential drug candidates for the treatment of retinitis pigmentosa. Journal of Enzyme Inhibition and Medicinal Chemistry, 32(1), 522–526. https://doi.org/10.1080/14756366.2016.1265522
Medina-Rodríguez, E. M., Bribián, A., Boyd, A., Palomo, V., Pastor, J., Lagares, A., Gil, C., Martínez, A., Williams, A., & de Castro, F. (2017). Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis. Scientific Reports, 7(1). https://doi.org/10.1038/srep43545
García, A. M., Salado, I. G., Perez, D. I., Brea, J., Morales-García, J. A., González-García, A., Cadavid, M. I., Loza, M. I., Luque, F. J., Perez-Castillo, A., Martinez, A., & Gil, C. (2017). Pharmacological Tools Based on Imidazole Scaffold Proved the Utility of Pde10A Inhibitors for Parkinson’S Disease. Future Medicinal Chemistry, 9(8), 731–748. https://doi.org/10.4155/fmc-2017-0005
Salado, I. G., Zaldivar-Diez, J., Sebastián-Pérez, V., Li, L., Geiger, L., González, S., Campillo, N. E., Gil, C., Morales, A. V., Perez, D. I., & Martinez, A. (2017). Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents. European Journal of Medicinal Chemistry, 138, 328–342. https://doi.org/10.1016/j.ejmech.2017.06.060
Pardo, M., Cheng, Y., Velmeshev, D., Magistri, M., Eldar-Finkelman, H., Martinez, A., Faghihi, M. A., Jope, R. S., & Beurel, E. (2017). Intranasal siRNA administration reveals IGF2 deficiency contributes to impaired cognition in Fragile X syndrome mice. JCI Insight, 2(6). https://doi.org/10.1172/jci.insight.91782
Mansilla, A., Chaves-Sanjuan, A., Campillo, N. E., Semelidou, O., Martínez-González, L., Infantes, L., González-Rubio, J. M., Gil, C., Conde, S., Skoulakis, E. M. C., Ferrús, A., Martínez, A., & Sánchez-Barrena, M. J. (2017). Interference of the complex between NCS-1 and Ric8a with phenothiazines regulates synaptic function and is an approach for fragile X syndrome. Proceedings of the National Academy of Sciences, 114(6). https://doi.org/10.1073/pnas.1611089114
Contreras, A., Del Rio, D., Martínez, A., Gil, C., Morales, L., Ruiz-Gayo, M., & Del Olmo, N. (2017). Inhibition of hippocampal long-term potentiation by high-fat diets. NeuroReport, 28(6), 354–359. https://doi.org/10.1097/wnr.0000000000000774
Huang, S., Wang, H., Turlova, E., Abussaud, A., Ji, X., Britto, L. R., Miller, S. P., Martinez, A., Sun, H., & Feng, Z. (2017). GSK‐3β inhibitor TDZD‐8 reduces neonatal hypoxic‐ischemic brain injury in mice. CNS Neuroscience & Therapeutics, 23(5), 405–415. Portico. https://doi.org/10.1111/cns.12683
Chierrito, T. P. C., Pedersoli-Mantoani, S., Roca, C., Requena, C., Sebastian-Perez, V., Castillo, W. O., Moreira, N. C. S., Pérez, C., Sakamoto-Hojo, E. T., Takahashi, C. S., Jiménez-Barbero, J., Cañada, F. J., Campillo, N. E., Martinez, A., & Carvalho, I. (2017). From dual binding site acetylcholinesterase inhibitors to allosteric modulators: A new avenue for disease-modifying drugs in Alzheimer’s disease. European Journal of Medicinal Chemistry, 139, 773–791. https://doi.org/10.1016/j.ejmech.2017.08.051
Martinez, A., Palomo Ruiz, M. del V., Perez, D. I., & Gil, C. (2017). Drugs in clinical development for the treatment of amyotrophic lateral sclerosis. Expert Opinion on Investigational Drugs, 26(4), 403–414. https://doi.org/10.1080/13543784.2017.1302426
Martinez, A., & Gil, C. (2017). Medicinal Chemistry Strategies to Discover New Leishmanicidal Drugs. Drug Discovery for Leishmaniasis, 153–178. https://doi.org/10.1039/9781788010177-00153
Martín-Álvarez, R., Paúl-Fernández, N., Palomo, V., Gil, C., Martínez, A., & Mengod, G. (2017). A preliminary investigation of phoshodiesterase 7 inhibitor VP3.15 as therapeutic agent for the treatment of experimental autoimmune encephalomyelitis mice. Journal of Chemical Neuroanatomy, 80, 27–36. https://doi.org/10.1016/j.jchemneu.2016.12.001
Palomo, V., Perez, D. I., Roca, C., Anderson, C., Rodríguez-Muela, N., Perez, C., Morales-Garcia, J. A., Reyes, J. A., Campillo, N. E., Perez-Castillo, A. M., Rubin, L. L., Timchenko, L., Gil, C., & Martinez, A. (2017). Subtly Modulating Glycogen Synthase Kinase 3 β: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases. Journal of Medicinal Chemistry, 60(12), 4983–5001. https://doi.org/10.1021/acs.jmedchem.7b00395
Morales-Garcia, J. A., Salado, I. G., Sanz-San Cristobal, M., Gil, C., Pérez-Castillo, A., Martínez, A., & Pérez, D. I. (2017). Biological and Pharmacological Characterization of Benzothiazole-Based CK-1δ Inhibitors in Models of Parkinson’s Disease. ACS Omega, 2(8), 5215–5220. https://doi.org/10.1021/acsomega.7b00869
García, A., Brea, J., González-García, A., Pérez, C., Cadavid, M. I., Loza, M. I., Martinez, A., & Gil, C. (2017). Targeting PDE10A GAF Domain with Small Molecules: A Way for Allosteric Modulation with Anti-Inflammatory Effects. Molecules, 22(9), 1472. https://doi.org/10.3390/molecules22091472
Sebastián-Pérez, V., Roca, C., Awale, M., Reymond, J.-L., Martinez, A., Gil, C., & Campillo, N. E. (2017). Medicinal and Biological Chemistry (MBC) Library: An Efficient Source of New Hits. Journal of Chemical Information and Modeling, 57(9), 2143–2151. https://doi.org/10.1021/acs.jcim.7b00401
Di Martino, R. M. C., De Simone, A., Andrisano, V., Bisignano, P., Bisi, A., Gobbi, S., Rampa, A., Fato, R., Bergamini, C., Perez, D. I., Martinez, A., Bottegoni, G., Cavalli, A., & Belluti, F. (2016). Versatility of the Curcumin Scaffold: Discovery of Potent and Balanced Dual BACE-1 and GSK-3β Inhibitors. Journal of Medicinal Chemistry, 59(2), 531–544. https://doi.org/10.1021/acs.jmedchem.5b00894
Wang, H., Huang, S., Yan, K., Fang, X., Abussaud, A., Martinez, A., Sun, H.-S., & Feng, Z.-P. (2016). Tideglusib, a chemical inhibitor of GSK3β, attenuates hypoxic-ischemic brain injury in neonatal mice. Biochimica et Biophysica Acta (BBA) - General Subjects, 1860(10), 2076–2085. https://doi.org/10.1016/j.bbagen.2016.06.027
Alquezar, C., Salado, I. G., de la Encarnación, A., Pérez, D. I., Moreno, F., Gil, C., de Munain, A. L., Martínez, A., & Martín-Requero, Á. (2016). Targeting TDP-43 phosphorylation by Casein Kinase-1δ inhibitors: a novel strategy for the treatment of frontotemporal dementia. Molecular Neurodegeneration, 11(1). https://doi.org/10.1186/s13024-016-0102-7
Cheng, Y., Pardo, M., Armini, R. de S., Martinez, A., Mouhsine, H., Zagury, J.-F., Jope, R. S., & Beurel, E. (2016). Stress-induced neuroinflammation is mediated by GSK3-dependent TLR4 signaling that promotes susceptibility to depression-like behavior. Brain, Behavior, and Immunity, 53, 207–222. https://doi.org/10.1016/j.bbi.2015.12.012
de Munck, E., Palomo, V., Muñoz-Sáez, E., Perez, D. I., Gómez-Miguel, B., Solas, M. T., Gil, C., Martínez, A., & Arahuetes, R. M. (2016). Small GSK-3 Inhibitor Shows Efficacy in a Motor Neuron Disease Murine Model Modulating Autophagy. PLOS ONE, 11(9), e0162723. https://doi.org/10.1371/journal.pone.0162723
Mantoani, S., Chierrito, T., Vilela, A., Cardoso, C., Martínez, A., & Carvalho, I. (2016). Novel Triazole-Quinoline Derivatives as Selective Dual Binding Site Acetylcholinesterase Inhibitors. Molecules, 21(2), 193. https://doi.org/10.3390/molecules21020193
M. Garcia, A., Martinez, A., & Gil, C. (2016). Enhancing cAMP Levels as Strategy for the Treatment of Neuropsychiatric Disorders. Current Topics in Medicinal Chemistry, 16(29), 3527–3535. https://doi.org/10.2174/1568026616666160426151306
Silva, T., Mohamed, T., Shakeri, A., Rao, P. P. N., Martínez-González, L., Pérez, D. I., Martínez, A., Valente, M. J., Garrido, J., Uriarte, E., Serrão, P., Soares-da-Silva, P., Remião, F., & Borges, F. (2016). Development of Blood–Brain Barrier Permeable Nitrocatechol-Based CatecholO-Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity. Journal of Medicinal Chemistry, 59(16), 7584–7597. https://doi.org/10.1021/acs.jmedchem.6b00666
Morales-Garcia, J. A., Echeverry-Alzate, V., Alonso-Gil, S., Sanz-SanCristobal, M., Lopez-Moreno, J. A., Gil, C., Martinez, A., Santos, A., & Perez-Castillo, A. (2016). Phosphodiesterase7 Inhibition Activates Adult Neurogenesis in Hippocampus and Subventricular Zone In Vitro and In Vivo. Stem Cells, 35(2), 458–472. https://doi.org/10.1002/stem.2480
Sebastián-Pérez, V., Manoli, M.-T., Pérez, D. I., Gil, C., Mellado, E., Martínez, A., Espeso, E. A., & Campillo, N. E. (2016). New applications for known drugs: Human glycogen synthase kinase 3 inhibitors as modulators of Aspergillus fumigatus growth. European Journal of Medicinal Chemistry, 116, 281–289. https://doi.org/10.1016/j.ejmech.2016.03.035
Morales-Garcia, J. A., Aguilar-Morante, D., Hernandez-Encinas, E., Alonso-Gil, S., Gil, C., Martinez, A., Santos, A., & Perez-Castillo, A. (2015). Silencing phosphodiesterase 7B gene by lentiviral-shRNA interference attenuates neurodegeneration and motor deficits in hemiparkinsonian mice. Neurobiology of Aging, 36(2), 1160–1173. https://doi.org/10.1016/j.neurobiolaging.2014.10.008
Morales-Garcia, J. A., Alonso-Gil, S., Gil, C., Martinez, A., Santos, A., & Perez-Castillo, A. (2015). Phosphodiesterase 7 Inhibition Induces Dopaminergic Neurogenesis in Hemiparkinsonian Rats. Stem Cells Translational Medicine, 4(6), 564–575. https://doi.org/10.5966/sctm.2014-0277
Mestre, L., Redondo, M., Carrillo‐Salinas, F. J., Morales‐García, J. A., Alonso‐Gil, S., Pérez‐Castillo, A., Gil, C., Martínez, A., & Guaza, C. (2015). PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis. British Journal of Pharmacology, 172(17), 4277–4290. Portico. https://doi.org/10.1111/bph.13192
de Munck, E., Muñoz-Sáez, E., Miguel, B. G., Solas, M. T., Martínez, A., & Arahuetes, R. M. (2015). Morphometric and neurochemical alterations found in l-BMAA treated rats. Environmental Toxicology and Pharmacology, 39(3), 1232–1245. https://doi.org/10.1016/j.etap.2015.04.022
Pardo, M., King, M. K., Perez-Costas, E., Melendez-Ferro, M., Martinez, A., Beurel, E., & Jope, R. S. (2015). Impairments in cognition and neural precursor cell proliferation in mice expressing constitutively active glycogen synthase kinase-3. Frontiers in Behavioral Neuroscience, 9. https://doi.org/10.3389/fnbeh.2015.00055
Perez, D., Martinez, A., Gil, C., & Campillo, N. (2015). From Bitopic Inhibitors to Multitarget Drugs for the Future Treatment of Alzheimer’s Disease. Current Medicinal Chemistry, 22(33), 3789–3806. https://doi.org/10.2174/0929867322666150812145825
Martinez, A., & Gil, C. (2015). Chapter 9. Heterocycles Containing Nitrogen and Sulfur as Potent Biologically Active Scaffolds. Privileged Scaffolds in Medicinal Chemistry, 231–261. https://doi.org/10.1039/9781782622246-00231
Silva, T., Bravo, J., Summavielle, T., Remião, F., Pérez, C., Gil, C., Martínez, A., & Borges, F. (2015). Biology-oriented development of novel lipophilic antioxidants with neuroprotective activity. RSC Advances, 5(21), 15800–15811. https://doi.org/10.1039/c4ra15164j
Muñoz-Sáez, E., de Munck García, E., Arahuetes Portero, R. M., Martínez, A., Solas Alados, M. T., & Miguel, B. G. (2015). Analysis of β-N-methylamino- l -alanine (L-BMAA) neurotoxicity in rat cerebellum. NeuroToxicology, 48, 192–205. https://doi.org/10.1016/j.neuro.2015.04.001
Prati, F., De Simone, A., Armirotti, A., Summa, M., Pizzirani, D., Scarpelli, R., Bertozzi, S. M., Perez, D. I., Andrisano, V., Perez-Castillo, A., Monti, B., Massenzio, F., Polito, L., Racchi, M., Sabatino, P., Bottegoni, G., Martinez, A., Cavalli, A., & Bolognesi, M. L. (2015). 3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3β Fragment Hits against Alzheimer’s Disease. ACS Chemical Neuroscience, 6(10), 1665–1682. https://doi.org/10.1021/acschemneuro.5b00121
Sastre, A., Campillo, N. E., Gil, C., & Martinez, A. (2015). Therapeutic approaches for the future treatment of Fragile X. Current Opinion in Behavioral Sciences, 4, 6–21. https://doi.org/10.1016/j.cobeha.2015.01.003
Martinez, A., & Gil, C. (2014). cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases. Expert Opinion on Therapeutic Patents, 24(12), 1311–1321. https://doi.org/10.1517/13543776.2014.968127
Salado, I. G., Redondo, M., Bello, M. L., Perez, C., Liachko, N. F., Kraemer, B. C., Miguel, L., Lecourtois, M., Gil, C., Martinez, A., & Perez, D. I. (2014). Protein Kinase CK-1 Inhibitors As New Potential Drugs for Amyotrophic Lateral Sclerosis. Journal of Medicinal Chemistry, 57(6), 2755–2772. https://doi.org/10.1021/jm500065f
Garcia, A. M., Redondo, M., Martinez, A., & Gil, C. (2014). Phosphodiesterase 10 Inhibitors: New Disease Modifying Drugs for Parkinson’s Disease? Current Medicinal Chemistry, 21(10), 1171–1187. https://doi.org/10.2174/0929867321666131228221749
García, A. M., Brea, J., Morales-García, J. A., Perez, D. I., González, A., Alonso-Gil, S., Gracia-Rubio, I., Ros-Simó, C., Conde, S., Cadavid, M. I., Loza, M. I., Perez-Castillo, A., Valverde, O., Martinez, A., & Gil, C. (2014). Modulation of cAMP-Specific PDE without Emetogenic Activity: New Sulfide-Like PDE7 Inhibitors. Journal of Medicinal Chemistry, 57(20), 8590–8607. https://doi.org/10.1021/jm501090m
Franklin, A. V., King, M. K., Palomo, V., Martinez, A., McMahon, L. L., & Jope, R. S. (2014). Glycogen Synthase Kinase-3 Inhibitors Reverse Deficits in Long-term Potentiation and Cognition in Fragile X Mice. Biological Psychiatry, 75(3), 198–206. https://doi.org/10.1016/j.biopsych.2013.08.003
Morales-Garcia, J. A., Palomo, V., Redondo, M., Alonso-Gil, S., Gil, C., Martinez, A., & Perez-Castillo, A. (2014). Crosstalk between Phosphodiesterase 7 and Glycogen Synthase Kinase-3: Two Relevant Therapeutic Targets for Neurological Disorders. ACS Chemical Neuroscience, 5(3), 194–204. https://doi.org/10.1021/cn400166d
Vida, M., Rivera, P., Gavito, A. L., Suárez, J., Pavón, F. J., Arrabal, S., Romero-Cuevas, M., Bautista, D., Martínez, A., de Fonseca, F. R., Serrano, A., & Baixeras, E. (2014). CB1 Blockade Potentiates Down-Regulation of Lipogenic Gene Expression in Perirenal Adipose Tissue in High Carbohydrate Diet-Induced Obesity. PLoS ONE, 9(2), e90016. https://doi.org/10.1371/journal.pone.0090016
Prati, F., De Simone, A., Bisignano, P., Armirotti, A., Summa, M., Pizzirani, D., Scarpelli, R., Perez, D. I., Andrisano, V., Perez‐Castillo, A., Monti, B., Massenzio, F., Polito, L., Racchi, M., Favia, A. D., Bottegoni, G., Martinez, A., Bolognesi, M. L., & Cavalli, A. (2014). Multitarget Drug Discovery for Alzheimer’s Disease: Triazinones as BACE‐1 and GSK‐3β Inhibitors. Angewandte Chemie International Edition, 54(5), 1578–1582. Portico. https://doi.org/10.1002/anie.201410456
de Munck, E., Muñoz-Sáez, E., Miguel, B. G., Solas, M. T., Ojeda, I., Martínez, A., Gil, C., & Arahuetes, R. M. (2013). β-N-methylamino-l-alanine causes neurological and pathological phenotypes mimicking Amyotrophic Lateral Sclerosis (ALS): The first step towards an experimental model for sporadic ALS. Environmental Toxicology and Pharmacology, 36(2), 243–255. https://doi.org/10.1016/j.etap.2013.04.007
Redondo, M., Soteras, I., Brea, J., González-García, A., Cadavid, M. I., Loza, M. I., Martinez, A., Gil, C., & Campillo, N. E. (2013). Unraveling phosphodiesterase surfaces. Identification of phosphodiesterase 7 allosteric modulation cavities. European Journal of Medicinal Chemistry, 70, 781–788. https://doi.org/10.1016/j.ejmech.2013.10.035
Beurel, E., Kaidanovich-Beilin, O., Yeh, W.-I., Song, L., Palomo, V., Michalek, S. M., Woodgett, J. R., Harrington, L. E., Eldar-Finkelman, H., Martinez, A., & Jope, R. S. (2013). Regulation of Th1 Cells and Experimental Autoimmune Encephalomyelitis by Glycogen Synthase Kinase-3. The Journal of Immunology, 190(10), 5000–5011. https://doi.org/10.4049/jimmunol.1203057
Perez-Gonzalez, R., Pascual, C., Antequera, D., Bolos, M., Redondo, M., Perez, D. I., Pérez-Grijalba, V., Krzyzanowska, A., Sarasa, M., Gil, C., Ferrer, I., Martinez, A., & Carro, E. (2013). Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer’s disease. Neurobiology of Aging, 34(9), 2133–2145. https://doi.org/10.1016/j.neurobiolaging.2013.03.011
Martinez, A., Perez, D., & Gil, C. (2013). Lessons Learnt from Glycogen Synthase Kinase 3 Inhibitors Development for Alzheimer’s Disease. Current Topics in Medicinal Chemistry, 13(15), 1808–1819. https://doi.org/10.2174/15680266113139990138
Medina-Rodríguez, E. M., Arenzana, F. J., Pastor, J., Redondo, M., Palomo, V., García de Sola, R., Gil, C., Martínez, A., Bribián, A., & de Castro, F. (2013). Inhibition of endogenous phosphodiesterase 7 promotes oligodendrocyte precursor differentiation and survival. Cellular and Molecular Life Sciences, 70(18), 3449–3462. https://doi.org/10.1007/s00018-013-1340-2
Bidon-Chanal, A., Fuertes, A., Alonso, D., Pérez, D. I., Martínez, A., Luque, F. J., & Medina, M. (2013). Evidence for a new binding mode to GSK-3: Allosteric regulation by the marine compound palinurin. European Journal of Medicinal Chemistry, 60, 479–489. https://doi.org/10.1016/j.ejmech.2012.12.014
Lipina, T. V., Palomo, V., Gil, C., Martinez, A., & Roder, J. C. (2013). Dual inhibitor of PDE7 and GSK-3 – VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice. Neuropharmacology, 64, 205–214. https://doi.org/10.1016/j.neuropharm.2012.06.032
González‐García, C., Bravo, B., Ballester, A., Gómez‐Pérez, R., Eguiluz, C., Redondo, M., Martínez, A., Gil, C., & Ballester, S. (2013). Comparative assessment of PDE 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis. British Journal of Pharmacology, 170(3), 602–613. Portico. https://doi.org/10.1111/bph.12308
Martinez, A., & Gil, C. (2013). Phosphodiesterase Inhibitors as a New Therapeutic Approach for the Treatment of Parkinson’s Disease. Emerging Drugs and Targets for Parkinson’s Disease, 294–307. https://doi.org/10.1039/9781849737357-00294
Staderini, M., Aulić, S., Bartolini, M., Tran, H. N. A., González-Ruiz, V., Pérez, D. I., Cabezas, N., Martínez, A., Martín, M. A., Andrisano, V., Legname, G., Menéndez, J. C., & Bolognesi, M. L. (2013). A Fluorescent Styrylquinoline with Combined Therapeutic and Diagnostic Activities against Alzheimer’s and Prion Diseases. ACS Medicinal Chemistry Letters, 4(2), 225–229. https://doi.org/10.1021/ml3003605
Susín, C., Morales‐Garcia, J. A., Aguilar‐Morante, D., Palomo, V., Sanz‐Sancristobal, M., Alonso‐Gil, S., Gil, C., Santos, A., Martinez, A., & Perez‐Castillo, A. (2012). The new iminothiadiazole derivative VP1.14 ameliorates hippocampal damage after an excitotoxic injury. Journal of Neurochemistry, 122(6), 1193–1202. Portico. https://doi.org/10.1111/j.1471-4159.2012.07866.x
Redondo, M., Zarruk, J. G., Ceballos, P., Pérez, D. I., Pérez, C., Perez-Castillo, A., Moro, M. A., Brea, J., Val, C., Cadavid, M. I., Loza, M. I., Campillo, N. E., Martínez, A., & Gil, C. (2012). Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model. European Journal of Medicinal Chemistry, 47, 175–185. https://doi.org/10.1016/j.ejmech.2011.10.040
Redondo, M., Palomo, V., Brea, J., Pérez, D. I., Martín-Álvarez, R., Pérez, C., Paúl-Fernández, N., Conde, S., Cadavid, M. I., Loza, M. I., Mengod, G., Martínez, A., Gil, C., & Campillo, N. E. (2012). Identification in Silico and Experimental Validation of Novel Phosphodiesterase 7 Inhibitors with Efficacy in Experimental Autoimmune Encephalomyelitis Mice. ACS Chemical Neuroscience, 3(10), 793–803. https://doi.org/10.1021/cn300105c
Morales-Garcia, J. A., Luna-Medina, R., Alonso-Gil, S., Sanz-SanCristobal, M., Palomo, V., Gil, C., Santos, A., Martinez, A., & Perez-Castillo, A. (2012). Glycogen Synthase Kinase 3 Inhibition Promotes Adult Hippocampal Neurogenesis in Vitro and in Vivo. ACS Chemical Neuroscience, 3(11), 963–971. https://doi.org/10.1021/cn300110c
Redondo, M., Brea, J., Perez, D. I., Soteras, I., Val, C., Perez, C., Morales-García, J. A., Alonso-Gil, S., Paul-Fernandez, N., Martin-Alvarez, R., Cadavid, M. I., Loza, M. I., Perez-Castillo, A., Mengod, G., Campillo, N. E., Martinez, A., & Gil, C. (2012). Effect of Phosphodiesterase 7 (PDE7) Inhibitors in Experimental Autoimmune Encephalomyelitis Mice. Discovery of a New Chemically Diverse Family of Compounds. Journal of Medicinal Chemistry, 55(7), 3274–3284. https://doi.org/10.1021/jm201720d
Serrano, A., Pavón, F. J., Suarez, J., Rivera, P., Vida, M., Bermúdez-Silva, F. J., Alonso, M., Martínez, A., López-Ogalla, J., Alonso-Gascón, M., Santamaría, G., Romero-Cuevas, M., Pérez-Valero, V., Baixeras, E., & Rodríguez de Fonseca, F. (2012). Adiponectin promoter activator NP-1 reduces body weight and hepatic steatosis in high-fat diet-fed animals. American Journal of Physiology-Endocrinology and Metabolism, 302(7), E817–E830. https://doi.org/10.1152/ajpendo.00468.2011
Chiriano, G., De Simone, A., Mancini, F., Perez, D. I., Cavalli, A., Bolognesi, M. L., Legname, G., Martinez, A., Andrisano, V., Carloni, P., & Roberti, M. (2012). A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation. European Journal of Medicinal Chemistry, 48, 206–213. https://doi.org/10.1016/j.ejmech.2011.12.016
Pérez, D. I., Pistolozzi, M., Palomo, V., Redondo, M., Fortugno, C., Gil, C., Felix, G., Martinez, A., & Bertucci, C. (2012). 5-Imino-1,2-4-thiadiazoles and quinazolines derivatives as glycogen synthase kinase 3β (GSK-3β) and phosphodiesterase 7 (PDE7) inhibitors: Determination of blood–brain barrier penetration and binding to human serum albumin. European Journal of Pharmaceutical Sciences, 45(5), 677–684. https://doi.org/10.1016/j.ejps.2012.01.007
Palomo, V., Perez, D. I., Perez, C., Morales-Garcia, J. A., Soteras, I., Alonso-Gil, S., Encinas, A., Castro, A., Campillo, N. E., Perez-Castillo, A., Gil, C., & Martinez, A. (2012). 5-Imino-1,2,4-Thiadiazoles: First Small Molecules As Substrate Competitive Inhibitors of Glycogen Synthase Kinase 3. Journal of Medicinal Chemistry, 55(4), 1645–1661. https://doi.org/10.1021/jm201463v
Morales-García, J. A., Susín, C., Alonso-Gil, S., Pérez, D. I., Palomo, V., Pérez, C., Conde, S., Santos, A., Gil, C., Martínez, A., & Pérez-Castillo, A. (2012). Glycogen Synthase Kinase-3 Inhibitors as Potent Therapeutic Agents for the Treatment of Parkinson Disease. ACS Chemical Neuroscience, 4(2), 350–360. https://doi.org/10.1021/cn300182g
Palomo, V., I. Perez, D., Gil, C., & Martinez, A. (2011). The Potential Role of Glycogen Synthase Kinase 3 Inhibitors as Amyotrophic Lateral Sclerosis Pharmacological Therapy. Current Medicinal Chemistry, 18(20), 3028–3034. https://doi.org/10.2174/092986711796391697
Perez, D. I., Palomo, V., Pérez, C., Gil, C., Dans, P. D., Luque, F. J., Conde, S., & Martínez, A. (2011). Switching Reversibility to Irreversibility in Glycogen Synthase Kinase 3 Inhibitors: Clues for Specific Design of New Compounds. Journal of Medicinal Chemistry, 54(12), 4042–4056. https://doi.org/10.1021/jm1016279
Crespillo, A., Alonso, M., Vida, M., Pavón, F., Serrano, A., Rivera, P., Romero‐Zerbo, Y., Fernández‐Llebrez, P., Martínez, A., Pérez‐Valero, V., Bermúdez‐Silva, F., Suárez, J., & de Fonseca, F. (2011). Reduction of body weight, liver steatosis and expression of stearoyl‐CoA desaturase 1 by the isoflavone daidzein in diet‐induced obesity. British Journal of Pharmacology, 164(7), 1899–1915. Portico. https://doi.org/10.1111/j.1476-5381.2011.01477.x
Perez, D. I., Gil, C., & Martinez, A. (2011). Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases. Medicinal Research Reviews, 31(6), 924–954. Portico. https://doi.org/10.1002/med.20207
Morales-Garcia, J. A., Redondo, M., Alonso-Gil, S., Gil, C., Perez, C., Martinez, A., Santos, A., & Perez-Castillo, A. (2011). Phosphodiesterase 7 Inhibition Preserves Dopaminergic Neurons in Cellular and Rodent Models of Parkinson Disease. PLoS ONE, 6(2), e17240. https://doi.org/10.1371/journal.pone.0017240
Paterniti, I., Mazzon, E., Gil, C., Impellizzeri, D., Palomo, V., Redondo, M., Perez, D. I., Esposito, E., Martinez, A., & Cuzzocrea, S. (2011). PDE 7 Inhibitors: New Potential Drugs for the Therapy of Spinal Cord Injury. PLoS ONE, 6(1), e15937. https://doi.org/10.1371/journal.pone.0015937
Crouch, P., Cole, A., Cousin, M., Martinez, A., & Kanninen, K. (2011). Glycogen Synthase Kinase‐3. International Journal of Alzheimer’s Disease, 2011(1). Portico. https://doi.org/10.4061/2011/279234
Martinez, A., Gil, C., & Perez, D. I. (2011). Glycogen Synthase Kinase 3 Inhibitors in the Next Horizon for Alzheimer′s Disease Treatment. International Journal of Alzheimer’s Disease, 2011(1). Portico. https://doi.org/10.4061/2011/280502
Eldar-Finkelman, H., & Martinez, A. (2011). GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS. Frontiers in Molecular Neuroscience, 4. https://doi.org/10.3389/fnmol.2011.00032
Palomo, V., Soteras, I., Perez, D. I., Perez, C., Gil, C., Campillo, N. E., & Martinez, A. (2011). Exploring the Binding Sites of Glycogen Synthase Kinase 3. Identification and Characterization of Allosteric Modulation Cavities. Journal of Medicinal Chemistry, 54(24), 8461–8470. https://doi.org/10.1021/jm200996g
Ermondi, G., Caron, G., Pintos, I. G., Gerbaldo, M., Pérez, M., Pérez, D. I., Gándara, Z., Martínez, A., Gómez, G., & Fall, Y. (2011). An application of two MIFs-based tools (Volsurf+ and Pentacle) to binary QSAR: The case of a palinurin-related data set of non-ATP competitive Glycogen Synthase Kinase 3β (GSK-3β) inhibitors. European Journal of Medicinal Chemistry, 46(3), 860–869. https://doi.org/10.1016/j.ejmech.2010.12.024
Martinez, A. (Ed.). (2010). Emerging Drugs and Targets for Alzheimer’s Disease. Drug Discovery. https://doi.org/10.1039/9781849731072
Perez, D. I., Gil, C., & Martinez, A. (2010). Chapter 9. Tau Protein Kinases Inhibitors: From the Bench to the Clinical Trials. Emerging Drugs and Targets for Alzheimer’s Disease, 173–194. https://doi.org/10.1039/9781849731065-00173
Perez, D. I., Conde, S., Pérez, C., Gil, C., Simon, D., Wandosell, F., Moreno, F. J., Gelpí, J. L., Luque, F. J., & Martínez, A. (2009). Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools. Bioorganic & Medicinal Chemistry, 17(19), 6914–6925. https://doi.org/10.1016/j.bmc.2009.08.042
Pérez, M., Pérez, D. I., Martínez, A., Castro, A., Gómez, G., & Fall, Y. (2009). The first enantioselective synthesis of palinurin. Chemical Communications, 22, 3252. https://doi.org/10.1039/b822679b
Fernández‐Bachiller, M. I., Pérez, C., Campillo, N. E., Páez, J. A., González‐Muñoz, G. C., Usán, P., García‐Palomero, E., López, M. G., Villarroya, M., García, A. G., Martínez, A., & Rodríguez‐Franco, M. I. (2009). Tacrine–Melatonin Hybrids as Multifunctional Agents for Alzheimer’s Disease, with Cholinergic, Antioxidant, and Neuroprotective Properties. ChemMedChem, 4(5), 828–841. Portico. https://doi.org/10.1002/cmdc.200800414
Castaño, T., Wang, H., Campillo, N. E., Ballester, S., González‐García, C., Hernández, J., Pérez, C., Cuenca, J., Pérez‐Castillo, A., Martínez, A., Huertas, O., Gelpí, J. L., Luque, F. J., Ke, H., & Gil, C. (2009). Synthesis, Structural Analysis, and Biological Evaluation of Thioxoquinazoline Derivatives as Phosphodiesterase 7 Inhibitors. ChemMedChem, 4(5), 866–876. Portico. https://doi.org/10.1002/cmdc.200900043
Valero, T., del Barrio, L., Egea, J., Cañas, N., Martínez, A., García, A. G., Villarroya, M., & López, M. G. (2009). NP04634 prevents cell damage caused by calcium overload and mitochondrial disruption in bovine chromaffin cells. European Journal of Pharmacology, 607(1–3), 47–53. https://doi.org/10.1016/j.ejphar.2009.02.021
Morales‐Garcia, J. A., Luna‐Medina, R., Martinez, A., Santos, A., & Perez‐Castillo, A. (2009). Anticonvulsant and neuroprotective effects of the novel calcium antagonist NP04634 on kainic acid‐induced seizures in rats. Journal of Neuroscience Research, 87(16), 3687–3696. Portico. https://doi.org/10.1002/jnr.22165
Martinez, A., Lahiri, D., Giacobini, E., & Greig, N. (2009). Editorial [Hot Topic:Advances in Alzheimer Therapy: Understanding Pharmacological Approaches to the Disease (Guest Editors: Ana Martinez, Debomoy K. Lahiri, Ezio Giacobini and Nigel H. Greig)]. Current Alzheimer Research, 6(2), 83–85. https://doi.org/10.2174/156720509787602924
Martinez, A. (2008). Preclinical efficacy on GSK‐3 inhibitors: Towards a future generation of powerful drugs. Medicinal Research Reviews, 28(5), 773–796. Portico. https://doi.org/10.1002/med.20119
García-Palomero, E., Muñoz, P., Usan, P., Garcia, P., Delgado, E., De Austria, C., Valenzuela, R., Rubio, L., Medina, M., & Martínez, A. (2008). Potent β-Amyloid Modulators. Neurodegenerative Diseases, 5(3–4), 153–156. Portico. https://doi.org/10.1159/000113688
Gil, C., Campillo, N. E., Perez, D. I., & Martinez, A. (2008). PDE7 inhibitors as new drugs for neurological and inflammatory disorders. Expert Opinion on Therapeutic Patents, 18(10), 1127–1139. https://doi.org/10.1517/13543776.18.10.1127
Castro, A., Encinas, A., Gil, C., Bräse, S., Porcal, W., Pérez, C., Moreno, F. J., & Martínez, A. (2008). Non-ATP competitive glycogen synthase kinase 3β (GSK-3β) inhibitors: Study of structural requirements for thiadiazolidinone derivatives. Bioorganic & Medicinal Chemistry, 16(1), 495–510. https://doi.org/10.1016/j.bmc.2007.09.016
Rosa, A. O., Egea, J., Martínez, A., García, A. G., & López, M. G. (2008). Neuroprotective effect of the new thiadiazolidinone NP00111 against oxygen-glucose deprivation in rat hippocampal slices: Implication of ERK1/2 and PPARγ receptors. Experimental Neurology, 212(1), 93–99. https://doi.org/10.1016/j.expneurol.2008.03.008
Martinez, A., & Perez, D. I. (2008). GSK-3 Inhibitors: A Ray of Hope for the Treatment of Alzheimer’s Disease? Journal of Alzheimer’s Disease, 15(2), 181–191. https://doi.org/10.3233/jad-2008-15204
Castro, A., Jerez, M. J., Gil, C., Calderón, F., Doménech, T., Nueda, A., & Martínez, A. (2008). CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example. European Journal of Medicinal Chemistry, 43(7), 1349–1359. https://doi.org/10.1016/j.ejmech.2007.10.027
Rosa, A. O., Kaster, M. P., Binfaré, R. W., Morales, S., Martín-Aparicio, E., Navarro-Rico, M. L., Martinez, A., Medina, M., García, A. G., López, M. G., & Rodrigues, A. L. S. (2008). Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 32(6), 1549–1556. https://doi.org/10.1016/j.pnpbp.2008.05.020
Martinez, A. (2008). S4‐02–03: TDZDS: Can we target tau, beta‐amyloid and neurodegeneration simultaneously? Alzheimer’s & Dementia, 4(4S_Part_5). Portico. https://doi.org/10.1016/j.jalz.2008.05.481
Luna-Medina, R., Cortes-Canteli, M., Sanchez-Galiano, S., Morales-Garcia, J. A., Martinez, A., Santos, A., & Perez-Castillo, A. (2007). NP031112, a Thiadiazolidinone Compound, Prevents Inflammation and Neurodegeneration under Excitotoxic Conditions: Potential Therapeutic Role in Brain Disorders. The Journal of Neuroscience, 27(21), 5766–5776. https://doi.org/10.1523/jneurosci.1004-07.2007
Hamann, M., Alonso, D., Martín-Aparicio, E., Fuertes, A., Pérez-Puerto, M. J., Castro, A., Morales, S., Navarro, M. L., del Monte-Millán, M., Medina, M., Pennaka, H., Balaiah, A., Peng, J., Cook, J., Wahyuono, S., & Martínez, A. (2007). Glycogen Synthase Kinase-3 (GSK-3) Inhibitory Activity and Structure–Activity Relationship (SAR) Studies of the Manzamine Alkaloids. Potential for Alzheimer’s Disease. Journal of Natural Products, 70(9), 1397–1405. https://doi.org/10.1021/np060092r
Castro, A., & Martinez, A. (2006). Targeting Beta-Amyloid Pathogenesis Through Acetylcholinesterase Inhibitors. Current Pharmaceutical Design, 12(33), 4377–4387. https://doi.org/10.2174/138161206778792985
Alonso, D., & Martínez, A. (2006). Marine Compounds as a New Source for Glycogen Synthase Kinase 3 Inhibitors. Glycogen Synthase Kinase 3 (GSK‐3) and Its Inhibitors, 307–331. Portico. https://doi.org/10.1002/0470052171.ch16
Rao, K. V., Donia, M. S., Peng, J., Garcia-Palomero, E., Alonso, D., Martinez, A., Medina, M., Franzblau, S. G., Tekwani, B. L., Khan, S. I., Wahyuono, S., Willett, K. L., & Hamann, M. T. (2006). Manzamine B and E and Ircinal A Related Alkaloids from an Indonesian Acanthostrongylophora Sponge and Their Activity against Infectious, Tropical Parasitic, and Alzheimer’s Diseases. Journal of Natural Products, 69(7), 1034–1040. https://doi.org/10.1021/np0601399
Maraschiello, C., Vilageliu, J., Dorronsoro, I., Martinez, A., Floriano, P., & Gómez‐Acebo, E. (2006). Enantioselective LC/MS method for the determination of an antimalarial agent Fenozan B07 in dog plasma. Chirality, 18(5), 297–305. Portico. https://doi.org/10.1002/chir.20253
Martinez, A. (2006). S4–04–06: Thiadiazolidindiones, selective glycogen synthase kinase–3 inhibitors as potential therapeutic agents for Alzheimer’s disease and other tauopathies. Alzheimer’s & Dementia, 2(3S_Part_3). Portico. https://doi.org/10.1016/j.jalz.2006.05.289
Martinez, A., Alonso, M., Castro, A., Dorronsoro, I., Gelpí, J. L., Luque, F. J., Pérez, C., & Moreno, F. J. (2005). SAR and 3D-QSAR Studies on Thiadiazolidinone Derivatives: Exploration of Structural Requirements for Glycogen Synthase Kinase 3 Inhibitors. Journal of Medicinal Chemistry, 48(23), 7103–7112. https://doi.org/10.1021/jm040895g
Luna-Medina, R., Cortes-Canteli, M., Alonso, M., Santos, A., Martínez, A., & Perez-Castillo, A. (2005). Regulation of Inflammatory Response in Neural Cells in Vitro by Thiadiazolidinones Derivatives through Peroxisome Proliferator-activated Receptor γ Activation. Journal of Biological Chemistry, 280(22), 21453–21462. https://doi.org/10.1074/jbc.m414390200
Poltev, V. I., Gonzalez, E., Deriabina, A. S., Lozano, L., Martinez, A., Robinson, T., Gorb, L., & Leszczynski, J. (2005). Molecular mechanics description of cytosine energy and geometry using preliminary ab initio results. Journal of Molecular Structure: THEOCHEM, 729(1–2), 59–64. https://doi.org/10.1016/j.theochem.2004.12.045
Alonso, D., Castro, A., & Martinez, A. (2005). Marine compounds for the therapeutic treatment of neurological disorders. Expert Opinion on Therapeutic Patents, 15(10), 1377–1386. https://doi.org/10.1517/13543776.15.10.1377
Gil, C., Dorronsoro, I., Castro, A., & Martinez, A. (2005). Good oral absorption prediction on non-nucleoside benzothiadiazine dioxide human cytomegalovirus inhibitors using combined chromatographic and neuronal network techniques. Bioorganic & Medicinal Chemistry Letters, 15(7), 1919–1921. https://doi.org/10.1016/j.bmcl.2005.01.081
Muñoz-Ruiz, P., Rubio, L., García-Palomero, E., Dorronsoro, I., del Monte-Millán, M., Valenzuela, R., Usán, P., de Austria, C., Bartolini, M., Andrisano, V., Bidon-Chanal, A., Orozco, M., Luque, F. J., Medina, M., & Martínez, A. (2005). Design, Synthesis, and Biological Evaluation of Dual Binding Site Acetylcholinesterase Inhibitors: New Disease-Modifying Agents for Alzheimer’s Disease. Journal of Medicinal Chemistry, 48(23), 7223–7233. https://doi.org/10.1021/jm0503289
Rodríguez-Franco, M. I., Fernández-Bachiller, M. I., Pérez, C., Castro, A., & Martínez, A. (2005). Design and synthesis of N-benzylpiperidine–purine derivatives as new dual inhibitors of acetyl- and butyrylcholinesterase. Bioorganic & Medicinal Chemistry, 13(24), 6795–6802. https://doi.org/10.1016/j.bmc.2005.07.019
Alonso, D., Dorronsoro, I., Rubio, L., Muñoz, P., García-Palomero, E., Del Monte, M., Bidon-Chanal, A., Orozco, M., Luque, F. J., Castro, A., Medina, M., & Martínez, A. (2005). Donepezil–tacrine hybrid related derivatives as new dual binding site inhibitors of AChE. Bioorganic & Medicinal Chemistry, 13(24), 6588–6597. https://doi.org/10.1016/j.bmc.2005.09.029
Martinez, A., & Castro, A. (2005). Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer’s disease. Expert Opinion on Investigational Drugs, 15(1), 1–12. https://doi.org/10.1517/13543784.15.1.1
Rodrigo, J., Fernández-Vizarra, P., Castro-Blanco, S., Bentura, M. L., Nieto, M., Gómez-Isla, T., MartÍnez-Murillo, R., MartÍnez, A., Serrano, J., & Fernández, A. P. (2004). Nitric oxide in the cerebral cortex of amyloid-precursor protein (SW) Tg2576 transgenic mice. Neuroscience, 128(1), 73–89. https://doi.org/10.1016/j.neuroscience.2004.06.030
Alonso, M., & Martinez, A. (2004). GSK-3 Inhibitors: Discoveries and Developments. Current Medicinal Chemistry, 11(6), 755–763. https://doi.org/10.2174/0929867043455738
Dorronsoro, I., Chana, A., Abasolo, M. I., Castro, A., Gil, C., Stud, M., & Martinez, A. (2004). CODES/Neural Network Model: a Useful Tool for in Silico Prediction of Oral Absorption and Blood‐Brain Barrier Permeability of Structurally Diverse Drugs. QSAR & Combinatorial Science, 23(2–3), 89–98. Portico. https://doi.org/10.1002/qsar.200330858
Castro, A., Jerez, M. J., Gil, C., & Martinez, A. (2004). Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: Advances in the development of specific phosphodiesterase inhibitors. Medicinal Research Reviews, 25(2), 229–244. Portico. https://doi.org/10.1002/med.20020
Conde, S., Pérez, D. I., Martínez, A., Perez, C., & Moreno, F. J. (2003). Thienyl and Phenyl α-Halomethyl Ketones: New Inhibitors of Glycogen Synthase Kinase (GSK-3β) from a Library of Compound Searching. Journal of Medicinal Chemistry, 46(22), 4631–4633. https://doi.org/10.1021/jm034108b
Rodrı́guez-Franco, M. I., Dorronsoro, I., Castro, A., Martı́nez, A., Badı́a, A., & Baños, J. E. (2003). Synthesis and muscarinic activities of O-[(Benzyl- or benzoyl-pyrazolyl)propynyl]-oximes of N-methylpiperidinone, 3-tropinone, and 3-quinuclidinone. Bioorganic & Medicinal Chemistry, 11(10), 2263–2268. https://doi.org/10.1016/s0968-0896(03)00111-1
Martinez, A., Gil, C., Castro, A., Pérez, C., Prieto, C., & Otero, J. (2003). Benzothiadiazine dioxides (BTD) derivatives as non-nucleoside human cytomegalovirus (HCMV) inhibitors. study of structural requirements for biological activity☆. Bioorganic & Medicinal Chemistry, 11(11), 2395–2402. https://doi.org/10.1016/s0968-0896(03)00148-2
Morales-Alcelay, S., Rubio, L., & Martinez, A. (2003). AMPA Glutamate Receptors and Neuropathic Pain. Mini-Reviews in Medicinal Chemistry, 3(7), 757–763. https://doi.org/10.2174/1389557033487719
Castro, A., Conde, S., Rodriguez-Franco, M., & Martinez, A. (2002). Non-Cholinergic Pharmacotherapy Approaches to the Future Treatment of Alzheimers Disease. Mini-Reviews in Medicinal Chemistry, 2(1), 37–50. https://doi.org/10.2174/1389557023406610
Dorronsoro, I., Castro, A., & Martinez, A. (2002). Inhibitors of glycogen synthase kinase-3: future therapy for unmet medical needs? Expert Opinion on Therapeutic Patents, 12(10), 1527–1536. https://doi.org/10.1517/13543776.12.10.1527
Martinez, A., Castro, A., Dorronsoro, I., & Alonso, M. (2002). Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Medicinal Research Reviews, 22(4), 373–384. Portico. https://doi.org/10.1002/med.10011
Martinez, A., Alonso, M., Castro, A., Pérez, C., & Moreno, F. J. (2002). First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer’s Disease. Journal of Medicinal Chemistry, 45(6), 1292–1299. https://doi.org/10.1021/jm011020u
Silva, A. M. S., Pinto, D. C. G. A., Cavaleiro, J. A. S., Martínez, A., Castro, A., & Elguero, J. (2002). An Experimental NMR and Semi-Empirical Theoretical Study of the Conformation of Styrylchromones and Styryl Alkyl or Aryl Ketones (Benzylidene Ketones). Journal of Chemical Research, 2002(4), 162–164. https://doi.org/10.3184/030823402103171735
Martinez, A., Castro, A., Gil, C., & Perez, C. (2001). Recent strategies in the development of new human cytomegalovirus inhibitors. Medicinal Research Reviews, 21(3), 227–244. Portico. https://doi.org/10.1002/med.1008
Castro, A., & Martinez, A. (2001). Peripheral and Dual Binding Site Acetylcholinesterase Inhibitors: Implications in treatment of Alzheimers Disease. Mini-Reviews in Medicinal Chemistry, 1(3), 267–272. https://doi.org/10.2174/1389557013406864
Rodríguez-Franco, M. I., Dorronsoro, I., & Martínez, A. (2001). O-Pyrazolylpropynyl-Hydroxylamines as Versatile Intermediates in the Synthesis of Compounds of Pharmacological Interest. Synthesis, 2001(11), 1711–1715. https://doi.org/10.1055/s-2001-16768
Castro, A. (2001). CoMFA of benzyl derivatives of 2,1,3-benzo and benzothieno[3,2-a]thiadiazine 2,2-dioxides: clues for the design of phosphodiesterase 7 inhibitors. European Journal of Medicinal Chemistry, 36(4), 333–338. https://doi.org/10.1016/s0223-5234(01)01227-2
Martinez, A., Gil, C., Castro, A., Perez, C., Witvrouw, M., Pannecouque, C., Balzarini, J., & De Clercq, E. (2001). Anti-HIV-1 Activity of Benzothiadiazine Dioxide. Antiviral Chemistry and Chemotherapy, 12(6), 347–351. https://doi.org/10.1177/095632020101200604
Martinez, A., Esteban, A., Gil, C., Conde, S., Andrei, G., Snoeck, R., Balzarini, J., & De Clercq, E. (2000). Thienothiadiazine 2,2-Dioxide Acyclonucleosides: Synthesis and Antiviral Activity. Antiviral Chemistry and Chemotherapy, 11(3), 221–230. https://doi.org/10.1177/095632020001100305
Conde, S., López-Serrano, P., & Martı́nez, A. (2000). Regioselective lipase-catalysed γ-monoamidation of d-glutamic acid diesters: effect of the N-protecting group. Tetrahedron: Asymmetry, 11(12), 2537–2545. https://doi.org/10.1016/s0957-4166(00)00210-x
Castro, A., & Martinez, A. (2000). Novel agents for the treatment of human cytomegalovirus infection. Expert Opinion on Therapeutic Patents, 10(2), 165–177. https://doi.org/10.1517/13543776.10.2.165
Martinez, A., Gil, C., Perez, C., Castro, A., Prieto, C., Otero, J., Andrei, G., Snoeck, R., Balzarini, J., & De Clercq, E. (2000). Nonnucleoside Human Cytomegalovirus Inhibitors: Synthesis and Antiviral Evaluation of (Chlorophenylmethyl)benzothiadiazine Dioxide Derivatives. Journal of Medicinal Chemistry, 43(17), 3267–3273. https://doi.org/10.1021/jm000118q
Martinez, A., Fernandez, E., Castro, A., Conde, S., Rodriguez-Franco, I., Baños, J.-E., & Badia, A. (2000). N-Benzylpiperidine derivatives of 1,2,4-thiadiazolidinone as new acetylcholinesterase inhibitors. European Journal of Medicinal Chemistry, 35(10), 913–922. https://doi.org/10.1016/s0223-5234(00)01166-1
Martı́nez, A., Lanot, C., Perez, C., Castro, A., López-Serrano, P., & Conde, S. (2000). Lipase-catalysed synthesis of new acetylcholinesterase inhibitors: N-benzylpiperidine aminoacid derivatives. Bioorganic & Medicinal Chemistry, 8(4), 731–738. https://doi.org/10.1016/s0968-0896(00)00020-1
Rodrı́guez-Franco, M. I., Dorronsoro, I., Castro, A., & Martı́nez, A. (2000). Hindered Inversion/Rotation in Diheteroaryl Alkyl Amines with a N-(1-Pyrazolyl) Group: Dynamic NMR and Molecular Modelling Studies. Tetrahedron, 56(12), 1739–1743. https://doi.org/10.1016/s0040-4020(99)01086-8
Martínez, A., Castro, A., Gil, C., Miralpeix, M., Segarra, V., Doménech, T., Beleta, J., Palacios, J. M., Ryder, H., Miró, X., Bonet, C., Casacuberta, J. M., Azorín, F., Piña, B., & Puigdoménech, P. (2000). Benzyl Derivatives of 2,1,3-Benzo- and Benzothieno[3,2-a]thiadiazine 2,2-Dioxides: First Phosphodiesterase 7 Inhibitors. Journal of Medicinal Chemistry, 43(4), 683–689. https://doi.org/10.1021/jm990382n
Martinez, A., Gil, C., Abasolo, M. I., Castro, A., Bruno, A. M., Perez, C., Prieto, C., & Otero, J. (2000). Benzothiadiazine Dioxide Dibenzyl Derivatives as Potent Human Cytomegalovirus Inhibitors: Synthesis and Comparative Molecular Field Analysis. Journal of Medicinal Chemistry, 43(17), 3218–3225. https://doi.org/10.1021/jm000033p
Castro, A., & Martinez, A. (2000). Inhibition of tau phosphorylation: a new therapeutic strategy for the treatment of Alzheimer’s disease and other neurodegenerative disorders. Expert Opinion on Therapeutic Patents, 10(10), 1519–1527. https://doi.org/10.1517/13543776.10.10.1519
Rodríguez-Franco, M. I., San Lorenzo, P., Martínez, A., & Navarro, P. (1999). Selective dopamine receptors: Synthesis, complexing properties, and molecular modelling studies of new podands derived from 4-hydroxy-1H-pyrazole. Tetrahedron, 55(9), 2763–2772. https://doi.org/10.1016/s0040-4020(99)00047-2
Castro, A., Gil, C., & Martínez, A. (1999). On the tautomerism of 2,1,3-benzothiadiazinone S,S-dioxide and related compounds. Tetrahedron, 55(42), 12405–12410. https://doi.org/10.1016/s0040-4020(99)00723-1
Martinez, A., Esteban, A. I., Castro, A., Gil, C., Conde, S., Andrei, G., Snoeck, R., Balzarini, J., & De Clercq, E. (1999). Novel Potential Agents for Human Cytomegalovirus Infection: Synthesis and Antiviral Activity Evaluation of Benzothiadiazine Dioxide Acyclonucleosides. Journal of Medicinal Chemistry, 42(7), 1145–1150. https://doi.org/10.1021/jm980327z
Castro, A., & Martinez, A. (1999). Intramolecular oxidative cyclizations in heteroarylthioureas: A versatile pathway to bridgehead heterocyclic systems. Journal of Heterocyclic Chemistry, 36(4), 991–995. Portico. https://doi.org/10.1002/jhet.5570360427
Martı́nez, A., Esteban, A. I., Herrero, A., Ochoa, C., Andrei, G., Snoeck, R., Balzarini, J., & Clercq, E. D. (1999). Imidazothiadiazine dioxides: synthesis and antiviral activity. Bioorganic & Medicinal Chemistry, 7(8), 1617–1623. https://doi.org/10.1016/s0968-0896(99)00114-5
Martinez, A., Gil, C., Perez, C., Castro, A., Prieto, C., & Otero, J. (1999). Chlorophenylmethyl benzothiadiazine dioxides derivatives: Potent human cytomegalovirus inhibitors. Bioorganic & Medicinal Chemistry Letters, 9(21), 3133–3136. https://doi.org/10.1016/s0960-894x(99)00538-7
Conde, S., López-Serrano, P., & Martı́nez, A. (1999). Candida antarctica lipase B catalysed amidation of pyroglutamic acid derivatives. A reaction survey. Journal of Molecular Catalysis B: Enzymatic, 7(5–6), 299–306. https://doi.org/10.1016/s1381-1177(99)00051-x
Juanes, O., Goya, P., & Martinez, A. (1998). Towards lipophilic derivatives of S‐adenosyl‐L‐methionine. Journal of Heterocyclic Chemistry, 35(3), 727–730. Portico. https://doi.org/10.1002/jhet.5570350338
Martinez, A., Castro, A., Arán, V. J., Cardelús, I., Llenas, J., & Palacios, J. M. (1998). Synthesis of nonsymmetrically 3,4‐disubstituted 1,2,5‐thiadiazole dioxides. Journal of Heterocyclic Chemistry, 35(2), 297–300. Portico. https://doi.org/10.1002/jhet.5570350206
Conde, S., Fierros, M., Rodrı́guez-Franco, M. I., & Puig, C. (1998). Resolution of 1-(4-amino-3-chloro-5-cyanophenyl)-2-bromo-1-ethanol by lipase mediated enantioselective alcoholysis, hydrolysis and acylation. Tetrahedron: Asymmetry, 9(13), 2229–2232. https://doi.org/10.1016/s0957-4166(98)00252-3
Segarra, V., Isabel Crespo, M., Pujol, F., Beleta, J., Doménech, T., Miralpeix, M., Palacios, J. M., Castro, A., & Martinez, A. (1998). Phosphodiesterase inhibitory properties of losartan. design and synthesis of new lead compounds. Bioorganic & Medicinal Chemistry Letters, 8(5), 505–510. https://doi.org/10.1016/s0960-894x(98)00058-4
Conde, S., López-Serrano, P., & Martínez, A. (1998). Lipase catalysed amidation of diethyl glutamate derivatives; peculiarities of ethyl S- and R-pyroglutamate. Biotechnology Letters, 20(3), 261–263. https://doi.org/10.1023/a:1005330003201
Conde, S., Esteban, A. I., Alonso, D., López-Serrano, P., & Martı́nez, A. (1998). Enzymatic alcoholysis of SO2-uracil analog diacyclonucleosides. Long-distance effect of the substituents on the regioselectivity. Journal of Molecular Catalysis B: Enzymatic, 4(5–6), 295–302. https://doi.org/10.1016/s1381-1177(98)00068-x
Esteban, A. I., Clercq, E. D., & Martinez, A. (1997). Synthesis and Antiviral Activity of Modified 1,2,6-Thiadiazine Dioxide Acyclonucleosides. Nucleosides and Nucleotides, 16(3), 265–276. https://doi.org/10.1080/07328319708001347
Rodríguez-Franco, M. I., Fierros, M., Martínez, A., Navarro, P., & Conde, S. (1997). Selective carriers of norepinephrine and ammonium ions: Ionophoric properties and molecular modelling studies of diester crown compounds containing a 1,3-bis(1H-pyrazol-1-yl)propane unit. Bioorganic & Medicinal Chemistry, 5(2), 363–367. https://doi.org/10.1016/s0968-0896(96)00250-7
Conde, S., López-Serrano, P., Fierros, M., Biezma, M. I., Martínez, A., & Rodríguez-Franco, M. I. (1997). Regioselective lipase-catalyzed synthesis of l-glutamic α-monoamide derivatives. Effect of the N-blocking group. Tetrahedron, 53(34), 11745–11752. https://doi.org/10.1016/s0040-4020(97)00741-2
Conde, S., Fierros, M., Dorronsoro, I., Luisa Jimeno, M., & Rodríguez-Franco, M. I. (1997). Regioselective lipase catalyzed synthesis of diester crowns. New asymmetric macrocycles containing a 1,3-bis(1H-pyrazol-1-yl)propane unit. Tetrahedron, 53(33), 11481–11488. https://doi.org/10.1016/s0040-4020(97)00727-8
Alcalde, E., Barat, A., Goya, P., Martinez, A., Ramirez, G., Roca, T., & Rozas, I. (1997). Molecular modeling of (E)-1-alkyl-4(3)-[2-(1H-azolyl)vinyl]-pyridinium salts and evaluation of their behavior towards choline acetyltransferase. Bioorganic & Medicinal Chemistry, 5(5), 949–954. https://doi.org/10.1016/s0968-0896(97)00033-3
Martínez, A., Ochoa, C., Rodríguez, J., Rodríguez, M., Castro, A., González, M., & Martínez, M. M. (1997). Comparative Molecular Field Analysis (CoMFA) on [6] + [6] Fused Pyrazines with Nematocide Properties. Quantitative Structure-Activity Relationships, 16(5), 372–376. Portico. https://doi.org/10.1002/qsar.19970160504
Martinez, A., Esteban, A. I., & Clercq, E. D. (1997). Benzothiadiazine dioxide acyclonucleosides as lead compounds for the development of new agents against human cytomegalovirus and varicella-zoster virus infections. Bioorganic & Medicinal Chemistry Letters, 7(8), 1031–1032. https://doi.org/10.1016/s0960-894x(97)00149-2
Martínez, A., Castro, A., Cardelús, I., Llenas, J., & Palacios, JoséM. (1997). Arylimino-1,2,4-thiadiazolidinones: A new family of potassium channel openers. Bioorganic & Medicinal Chemistry, 5(7), 1275–1283. https://doi.org/10.1016/s0968-0896(97)00077-1
Linares, A., Acosta, J. L., Martinez, A., & García-Laureiro, J. I. (1997). Applications of a statistical model to the analysis of the kinetic parameters in isothermal and non-isothermal crystallization of polymer blends based on PVDF. Polymer, 38(11), 2741–2746. https://doi.org/10.1016/s0032-3861(97)85609-1
Martinez, A., Castro, A., & Fayet, J. P. (1997). Base promoted transformation on thiadiazolopyridinium chlorides. Journal of Heterocyclic Chemistry, 34(1), 337–340. Portico. https://doi.org/10.1002/jhet.5570340153
Martinez, A., Castro, A., Fonseca, I., Martinez-Ripoll, M., H. Cano, F., & Albert, A. (1996). New Synthetic Route to of 1,2,4-Thiadiazolines and 1,3-Thiazolines via Thiadiazolopyridinium Salts. HETEROCYCLES, 43(12), 2657. https://doi.org/10.3987/com-96-7593
Singh, S. P., Kumar, D., Kumar, D., Martínez, A., & Elguero, J. (1996). Conformation and ortho steric effects in a series of 2‐(pyrazol‐1‐yl)quinolines. Journal of Heterocyclic Chemistry, 33(2), 323–326. Portico. https://doi.org/10.1002/jhet.5570330219
Kumar, D., Singh, S. P., Martínez, A., Fruchier, A., Elguero, J., Martínez-Ripoll, M., Carrió, J. S., & Virgili, A. (1995). The structure of the compounds resulting from the reaction of arylhydrazines with dehydroacetic acid: an NMR and crystallographic study. Tetrahedron, 51(16), 4891–4906. https://doi.org/10.1016/0040-4020(95)00172-5
Alcaide, B. (1995). The Regio- and Stereocontrolled Ring Opening of Heteroarylglycidates with Nitrogen Nucleophiles. Tetrahedron Letters, 36(30), 5417–5420. https://doi.org/10.1016/00404-0399(50)0994n-
Llamas-Saiz, A. L., Foces-Foces, C., Martínez, A., & Elguero, J. (1995). Semiempirical (AM1, PM3 and SAM1) calculations of the protonation enthalpies of proton sponges related to 1,8-diaminonaphthalene. Estimation of the aqueous basicity of new designed superbases. J. Chem. Soc., Perkin Trans. 2, 5, 923–927. https://doi.org/10.1039/p29950000923
Fierros, M., Conde, S., Martínez, A., Navarro, P., & Rodríguez-Franco, M. I. (1995). Regioselective Mucor miehei lipase catalyzed synthesis of podands containing a 1,3-bis(1H-Pyrazol-1-yl)propane unit. Tetrahedron, 51(8), 2417–2426. https://doi.org/10.1016/0040-4020(94)01106-a
Esteban, A. I., Juanes, O., Conde, S., Goya, P., De Clercq, E., & Martínez, A. (1995). New 1,2,6-thiadiazine dioxide acyclonucleosides: Synthesis and antiviral evaluation. Bioorganic & Medicinal Chemistry, 3(11), 1527–1535. https://doi.org/10.1016/0968-0896(95)00140-c
Castro, A., Martínez, A., Cardelús, I., & Llenas, J. (1995). Dioxides of bicyclic thiadiazines: a new family of smooth muscle relaxants. Bioorganic & Medicinal Chemistry, 3(2), 179–185. https://doi.org/10.1016/0968-0896(95)00012-6
Castro, A., & Martínez, A. (1994). Tautomerism of benzo- and cyclopenta-[1,2,6]thiadiazine S,S-dioxides. J. Chem. Soc., Perkin Trans. 2, 7, 1561–1564. https://doi.org/10.1039/p29940001561
Esteban, A. I., Juanes, O., Martínez, A., & Conde, S. (1994). Regioselective lipase-mediated acylation-deacylation in thiadiazine diacyclonucleosides. Tetrahedron, 50(48), 13865–13870. https://doi.org/10.1016/s0040-4020(01)85694-5
Avendaño, C., Espada, M., Ocaña, B., García-Granda, S., Díaz, M. del R., Tejerina, B., Gómez-Beltrán, F., Martínez, A., & Elguero, J. (1993). The problem of the existence of C(Ar)–H ⋯ N intramolecular hydrogen bonds in a family of 9-azaphenyl-9H-carbazoles. J. Chem. Soc., Perkin Trans. 2, 8, 1547–1555. https://doi.org/10.1039/p29930001547
Perrin, M., Thozet, A., Lecocq, S., Elguero, J., Martinez, A., & Fruchier, A. (1993). The molecular structure of 3(5)-methyl-4,5(3)-trimethylenepyrazole hydrochloride and its13C and15N NMR spectroscopy. Journal of Crystallographic and Spectroscopic Research, 23(12), 961–965. https://doi.org/10.1007/bf01185544
de la Cruz, A., Elguero, J., Goya, P., Martineza, A., & De Clercq, E. (1993). Synthesis and biological evaluation of 4-quinolone ribosides. Journal of the Chemical Society, Perkin Transactions 1, 7, 845. https://doi.org/10.1039/p19930000845
Klein, J. F., Pommelet, J. C., Chuche, J., Elguero, J., Goya, P., & Martinez, A. (1993). SO2 extrusion in 1,2,6-thiadiazine 1,1-dioxides: a novel synthesis of pyrazoles. Canadian Journal of Chemistry, 71(3), 410–412. https://doi.org/10.1139/v93-060
Brenner, I. B., & Dorfman, E. (1993). Application of ultrasonic nebulization for the determination of rare earth elements in phosphates and related sedimentary rocks using inductively coupled plasma atomic emission spectrometry with comments on dissolution procedures. Journal of Analytical Atomic Spectrometry, 8(6), 833. https://doi.org/10.1039/ja9930800833
de la Cruz, A., Elguero, J., Goya, P., Martínez, A., & Pfleiderer, W. (1992). Tautomerism and acidity in 4-quinolone-3-carboxylic acid derivatives. Tetrahedron, 48(29), 6135–6150. https://doi.org/10.1016/s0040-4020(01)89860-4
Alcalde, E., Roca, T., Barat, A., Ramirez, G., Goya, P., & Martinez, A. (1992). (E)-1-alkyl-[2-(1H-azol-2-yl)vinyl]pyridinium salts: theoretical analysis, synthesis and evaluation of their interaction with choline acetyltransferase. Bioorganic & Medicinal Chemistry Letters, 2(12), 1493–1496. https://doi.org/10.1016/s0960-894x(00)80415-1
Elguero, J., Martinez, A., Singh, S. P., & Kumar, D. (1991). Synthesis and NMR spectroscopy (1H 13C) of 1‐(2′‐benzothiazolyl)‐3(5),4‐polymethylenepyrazoles and related compounds. Journal of Heterocyclic Chemistry, 28(3), 647–651. Portico. https://doi.org/10.1002/jhet.5570280319
Herranz, R., Suárez-Gea, M. L., Vinuesa, S., García-López, M. T., & Martínez, A. (1991). Synthesis of Ψ[CH(CN)NH] pseudopeptides. A new peptide bond surrogate. Tetrahedron Letters, 32(51), 7579–7582. https://doi.org/10.1016/0040-4039(91)80539-i
de la Cruz, A., Elguero, J., Gotor, V., Goya, P., Martínez, A., & Moris, F. (1991). Lipase-Mediated Acylation of Acyclonucleosides. Application to Novel Fluoroquinolone Derivatives. Synthetic Communications, 21(14), 1477–1480. https://doi.org/10.1080/00397919108016421
de la Cruz, A., Elguero, J., Goya, P., & Martinez, A. (1990). Synthesis of a Valuable Precursor for the Preparation of Novel Quinolone Glycosides. Synlett, 1990(12), 753–754. https://doi.org/10.1055/s-1990-21239
Elguero, J., Goya, P., Martínez, A., Rozas, I., Mó, O., De Paz, J. L. G., & Yáñez, M. (1990). Structure of 1,2,6‐thiadiazine 1,1‐dioxides. Journal of Physical Organic Chemistry, 3(7), 470–476. Portico. https://doi.org/10.1002/poc.610030709
Goya, P., Martinez, A., & Jimeno, M. L. (1990). Rotational isomerism in 6-β-D-glucopyranosides of methyl-1,2,6-thiadiazin-3(2H)-one 1,1-dioxides. J. Chem. Soc., Perkin Trans. 2, 5, 783–786. https://doi.org/10.1039/p29900000783
Cruz, A. de la, Goya, P., Martínez, A., & Páez, J. A. (1990). Glycosides of Pyrido [2,3-c]-1,2,6-thiadiazine 2,2-Dioxides. Nucleosides and Nucleotides, 9(1), 69–79. https://doi.org/10.1080/07328319008045110
Elguero, J., Martíanez, A., Singh, S. P., Grover, M., & Tarar, L. S. (1990). A 1H and 13c Nmr study of the structure and tautomerism of 4‐pyrazolylpyrazolinones. Journal of Heterocyclic Chemistry, 27(4), 865–870. Portico. https://doi.org/10.1002/jhet.5570270409
Singh, S. P., Tarar, L. S., Vaid, R. K., Elguero, J., & Martínez, A. (1989). Reaction of 4‐hydrazinoquinolines with β‐diketones. Synthesis and spectroscopy (1h, 13c nmr, ms) of some pyrazolylquinolines. Journal of Heterocyclic Chemistry, 26(3), 733–738. Portico. https://doi.org/10.1002/jhet.5570260340
Elguero, J., Goya, P., Martinez, A., & Rozas, I. (1989). On the Tautomerism of 2‐Phenacyl‐4‐pyrimidinones and Related Compounds. Chemische Berichte, 122(5), 919–924. Portico. https://doi.org/10.1002/cber.19891220521
De La Cruz, A., Elguero, J., Goya, P., & Martinez, A. (1988). Synthesis and spectroscopic properties of N‐azolylpropanamides. Journal of Heterocyclic Chemistry, 25(1), 225–229. Portico. https://doi.org/10.1002/jhet.5570250135
Goya, P., & Martínez, A. (1988). Synthesis and Cytostatic Screening of an SO2 Analogue of Doridosine. Archiv Der Pharmazie, 321(2), 99–101. Portico. https://doi.org/10.1002/ardp.19883210213
Goya, P., Martínez, A., & Ochoa, C. (1987). Synthesis of 2S-Dioxo Isosteres of Purine and Pyrimidine Nucleosides IV. Selective Glycosylation of 4-Amino-5H-Imidazo [4, 5-c]-1, 2, 6-Thiadiazine 2, 2-Dioxide. Nucleosides, Nucleotides and Nucleic Acids, 6(3), 631–642. https://doi.org/10.1080/07328318708069992
Goya, P., & Martinez, A. (1986). N-Glucosyl-5-amino-4-carbamoyl- and 4-Ethoxycarbonylimidazoles as Potential Precursors of 4-Oxoimdazo[4,5-c]-1,2,6-thiadiazine 2,2-Dioxides. HETEROCYCLES, 24(12), 3451. https://doi.org/10.3987/r-1986-12-3451
Goya, P., Martinez, A., Ochoa, C., Stud, M., Jimeno, M. L., Foces-Foces, C., Cano, F. H., & Martinez-Ripoll, M. (1985). Synthesis and intramolecular cyclization of bisthiadiazinylmethane derivatives. Tetrahedron, 41(15), 3105–3116. https://doi.org/10.1016/s0040-4020(01)96663-3
Research lines:
There are no lines of investigation associated with this user.
Funding:
No funded projects.
More info
Spin-off: MOLEFY PHARMA
Participation in:
Other Participation: international, csicconexion, csicpt
